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Prostaglandin E2 (PGE2), the most abundant prostaglandin in mouse skin, has 
been shown to promote skin tumor development. EP1 is one of four PGE2 receptors. EP1 
mRNA levels analyzed by a quantitative real-time polymerase chain reaction were 
increased after treatments of 12-O-tetradecanoylphorbol 13-acetate (TPA) or ultraviolet 
light on skin as well as in 7,12 dimethylbenz[a]anthracene (DMBA)/TPA or UV-induced 
skin tumors. To determine whether the EP1 receptor levels affect skin tumor 
development, we generated BK5.EP1 transgenic mice which overexpress EP1 in the 
basal layer of the epidermis. The skins of these mice are histologically indistinguishable 
from wild type mice. To determine the role of EP1 in skin tumor development, a 
DMBA/TPA skin carcinogenesis protocol was used. EP1 transgenic mice had a reduced 
tumor multiplicity and a reduced tumor incidence compared to wild type mice, but had a 
higher papilloma to carcinoma conversion rate. In a DMBA-only skin carcinogenesis 
protocol, EP1 transgenic mice developed more tumors than wild type mice. The effect of 
EP1 on cell proliferation was measured in vivo. After TPA treatment, cell proliferation 
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was induced in both EP1 transgenic mice and wild type mice to a similar extent. 
However, 5 days after DMBA treatment, there were about 2-fold more proliferating cells 
in the basal layer of the epidermis of EP1 transgenic mouse skin than in wild type mice. 
To confirm that the enhanced tumor formation in transgenic mice is in fact PGE2 
dependent, EP1 transgenic mice were administered the selective cyclooxygenase-2 
inhibitor Celecoxib or a control diet starting 1 week before DMBA treatment. 
Surprisingly, there was no lesion development on mice that were fed Celecoxib. 
Histological sections of skin from Celecoxib-fed mice showed a fairly normal skin 
histology 2 weeks after DMBA treatment compared to the pronounced 
pseudocarcinomatous hyperplasia observed in control diet mice. Therefore, it can be 
concluded that EP1 signaling increases PGE2 production through COX-2 induction and 
promotes tumor development. 
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Chapter 1 Introduction and literature review 
1.1 SKIN CARCINOGENESIS  
1.1.1 Skin  
The skin is the largest organ in the body, forming a protective barrier against the 
environment in terms of ultraviolet (UV) rays, scratches, wounds and microbes and 
dehydration. The skin is separated into two parts by the basement membrane under which 
is the dermis, the connective tissue. Hair follicles, sweat glands, sebaceous glands and 
blood vessels are located in the dermis (Figure 1-1). Above the basement membrane is 
the epidermis which is composed primarily of keratinocytes (95%). Melanocytes, 
Langerhans cells (dendritic cells) and Merkel cells (sensory receptors) are also present in 
the epidermis (Janes, Lowell et al. 2002). The bottom layer of the epidermis is called the 
basal layer which is the only layer that proliferates and expresses keratin 5 (K5) and K14 
(Figure 1-2) (Fuchs and Cleveland 1998). K1 and K10 are expressed in the spinous layer 
and also used as early differentiation markers. Cytoskeletal keratin filaments are 
strengthened to provide mechanical strength against physical trauma (Segre 2006). Cells 
in the granular layer express involucrin, loricrin, filaggrin and keratinocyte 
transglutaminase and contain lamella granules which are filled with lipids that extrude to 
the cornified envelop (Yuspa 1994). These produce a water-impermeable seal that 
prevents the escape of fluid (Alonso and Fuchs 2003). Filaggrin aggregates keratin 
filaments into tight bundles and promotes collapse of the cell into a flat shape. The 
cornified layer is composed of terminally differentiated dead, flat and anucleated 
keratinocytes (corneocytes) (Candi, Schmidt et al. 2005). In the cornified envelope, 
involucrin is crosslinked with other proteins and also forms an exterior surface with 
 
 
Figure 1-1. Human skin structure. Epidermis (1) and Dermis (2) are separated by the 
basement membrane. Epidermis is mostly keratinocytes. In the dermis, hair 
follicle (4), sebaceous gland (5), sweat gland (6) and blood vessels are 






Figure 1-2. Human skin epidermis. Name of each layer and specific marker are shown. 
The bottom layer of the epidermis is the basal layer which expresses K5 and 
K14 and the only layer that proliferates. Ki-67 and PCNA (proliferating cell 
nuclear antigen) are proliferation markers. As keratinocytes move 
outerward, they form a cornified envelop and become flattened.   
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externalized lipids, mostly ceramides. Loricrin is a main structural protein in the cornified 
envelope (70~85 % of the total protein). In the cornified cells, fillagrin is degraded and 
hydrophilic amino acids contributes to retention of water and flexibility (Candi, Schmidt 
et al. 2005). Figure 3 shows human skin, but in mouse skin there are no sweat glands in 
the dermis and the epidermis is normally only two layers of cells and the suprabasal cells 
are relatively flat (Janes, Lowell et al. 2002). 
In normal human skin, cyclooxygenase -1 (COX-1) is expressed throughout the 
entire epidermis while COX-2 is slightly expressed only in suprabasal layers. In normal 
mouse skin, COX-2 is not expressed. COX-2 is important in normal skin physiology. In 
COX-2 deficient mouse epidermis, the proliferation index is about 30% reduced as 
compared to wild type mice (Tiano, Loftin et al. 2002). COX-2 deficient mice show 
accelerated epidermal differentiation. Keratin 5-driven COX-2 transgenic mice have 
sparse hair due to delayed hair follicle development, hyperplastic epidermis and 
sebaceous gland, and impaired differentiation (Lee, Mukhtar et al. 2003).   
 
1.1.2 Two-stage mouse skin carcinogenesis  
Multistage skin carcinogenesis is divided into three stages; initiation, promotion 
and progression (Figure 1-3). Initiation is achieved by a subcarcinogenic dose of a 
carcinogen. There is no morphological change in the epidermis following initiation. 
During initiation, a genetic mutation occurs following interaction of a chemical 
carcinogen (7,12-dimethylbenz[a]anthracene (DMBA), 3-methylcholanthrene, etc) or 
physical carcinogen (UV, X-rays, etc) and DNA in epidermal cells. To fix the mutation, 
DNA synthesis is required (Pitot and Dragan 1991). Therefore, basal cells and epidermal 
stem cells in hair follicles are targets for initiation. This initiation is irreversible. 
 
 
Figure 1-3. Multistage skin carcinogenesis model. In the initiation, genetic mutation 
occurs. In the promotion, initiated cells undergo clonal expansion. Because 
tumor promotion is a reversible step, repetitive application of a promoter is 
required. In the progression stage, benign papillomas undergo additional 
genetic changes and become squamous cell carcinomas (SCCs) which are 




In skin, the two most common experimental initiating agents are chemical 
carcinogens and UV light. DMBA is metabolized by CYP1B1 to reactive intermediates 
(Buters, Sakai et al. 1999). More than 90% of tumors initiated with DMBA have A182  
T transversion at codon 61 of c-Ha-ras (Quintanilla, Brown et al. 1986). This mutation 
causes Gln  Leu (Sekiya, Fushimi et al. 1984) and the mutation increases the 
transforming activity of c-H-ras (Der, Finkel et al. 1986).  
UV rays are divided into three layers based on wavelength. UVC is 200-280nm 
and absorbed by the ozone layer. UVA is 320-400nm and 90-99% of the sunlight that 
reaches the earth. UVB is 280-320nm and is 1-10% of sunlight. Both UVA and UVB 
cause cyclobutane-pyrimidine dimers but only UVB induces pyrimidine (6-4) 
pyrimidones (Cadet, Sage et al. 2005). These photoproducts cause mutations by C  T 
transversion. UV radiation induce C T transversion in p53, the tumor suppressor gene 
(Ziegler, Leffell et al. 1993). These photoproducts can be repaired by nucleotide excision 
repair (NER). As a result, Xeroderma pigmentosum patients who are genetically deficient 
in one of the genes in NER are sensitive to UV and develop multiple skin cancers 
(Cleaver 2005). Both UVA and UVB generate oxidative stress and cause 8-oxo-7,8-
dihydroxyguanine formation which causes G  T transversion (Cadet, Sage et al. 2005). 
Initiated cells undergo clonal expansion during promotion. Tumor promoters are 
not mutagenic but act via epigenetic mechanisms, inducing inflammation (edema, 
erythema, leukocyte infiltration of dermis), producing free radicals from 
polymorphonuclear leukocytes, increasing mitotic activity in the basal layer of the 
epidermis, producing more prostaglandin (PG) synthesis, decreasing the activities of 
superoxide dismutase and catalase and inducing ornithine decarboxylase, the rate-limiting 
enzyme in polyamine biosynthesis needed for DNA synthesis. This stage is a reversible 
step early on and requires repetitive application to develop a tumor but a tumor promoter 
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alone does not induce a tumor. In the skin, 12-O-tetradecanoylphorbol 13-acetate (TPA), 
fatty acid methyl esters, anthrones, retinoic acids and UV work as tumor promoters 
(DiGiovanni 1992).  
Protein kinase C (PKC) is a serine/threonine kinase and receptor for the tumor 
promoter TPA. PKC isoforms are classified into three groups; classical cPKC (α, βI, βII, 
and γ) are calcium-sensitive and need diacylglycerol (DAG) or phorbol esters for 
activation, novel nPKC (δ, ε, η, θ), are calcium-independent and need DAG or phorbol 
esters for activation, while atypical aPKC (ζ and ι/λ) isoforms are calcium independent 
and are not activated by TPA. All isomers require phosphatidylserine for activation. In 
response to TPA, PKC is activated and translocated from the cytosol to the membrane. 
Also, TPA or UV treatment releases the intramolecular inhibitory pseudosubstrate 
domain of PKC and leaves an active PKC catalytic domain (Breitkreutz, Braiman-
Wiksman et al. 2007).  
PKCα is expressed abundantly in the skin. Transgenic mice that overexpress 
PKCα have increased inflammatory responses including increased epidermal thickness, 
edema, inflammatory cytokines and chemokines. However, PKCα does not affect  
tumor promotion (Wang and Smart 1999). PKCδ is expressed in basal cells and is 
involved in early onset of differentiation. Interestingly, transgenic mice which 
overexpress PKCδ are resistant to DMBA/TPA-induced skin cancer development 
(Reddig, Dreckschmidt et al. 1999) but not resistant to UV-induced skin cancer 
development (Aziz, Wheeler et al. 2006). PKCη is expressed in the suprabasal layer. 
Overexpression of PKCη in human keratinocytes induces differentiation markers 
(involucrin and transglutaminase-1) (Ueda, Ohno et al. 1996). PKCη deficient mice are 
more susceptible to skin tumor formation (Chida, Hara et al. 2003). PKCε is expressed in 
the basal keratinocytes. Transgenic mice which overexpress PKCε show epidermal 
 8
hyperproliferation. Interestingly, these mice produce fewer papillomas but the 
progression rate to squamous cell carcinoma (SCC) was increased (Reddig, 
Dreckschmidt et al. 2000). 
Benign papillomas are not invasive. These benign tumors undergo additional 
genetic changes during progression and become SCCs which break through the basement 
membrane, grow rapidly, are invasive and metastatic and have a blood supply into the 
tumor (DiGiovanni 1992).  
 
1.1.3 Inflammation and cancer  
Inflammation is a tissue change in response to injury. Characteristics of 
inflammation are vasodilation, edema, clotting, migration of innate immune cells and 
swelling of tissue cells (Guyton 1996). Inflammation is one of the defense mechanisms 
used to protect tissue from damage. However, if the inflammation is not resolved 
completely and chronic inflammation takes place, it is no longer beneficial to the host 
(Katzung 1995). Chronic inflammation increases risk of cancer development in bladder, 
stomach, liver, colon and ovary (Moore, Owens et al. 1999). Reactive oxygen species 
generation during inflammation is important in initiation. During tumor promotion and 
tumor progression, cell proliferation, apoptosis and angiogenesis are affected by 
inflammation (Kundu and Surh 2008). Inflammatory molecules that are important in the 
tumor development are cytokines, nitric oxide, NF-κB and COX-2.  
In the skin, interleukin-1α (IL-1α) and tumor necrosis factor-α (TNF-α) are 
important cytokines. IL-1α mRNA was increased in skin after application of TPA on skin 
(Lee, Fischer et al. 1993). Intradermal injection of IL-1α increased vascular permeability, 
cell proliferation and inflammatory cell infiltration in the dermis. Injection of antibody 
aginst IL-1α prevented TPA induced vascular permeability, cell proliferation and 
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inflammatory cell infiltration in the dermis (Lee, Lockniskar et al. 1994). TNF-α is one of 
the important cytokines in tumorigenesis. Thus, TNF-α null mice and TNF-α receptor 
null mice are resistant to skin tumor development (Moore, Owens et al. 1999; Arnott, 
Scott et al. 2004). IL-1 and/or TNF- α can induce a variety of cytokines including IL-6, 
IL-8/neutrophil activating protein (NAP)-1, granulocyte/macrophage – colony 
stimulating factor (GM-CSF), G-CSF, and monocyte chemotactic and activating factor in 
the skin (Kupper 1990). Chemokines are induced by inflammatory cytokines and attract 
leukocytes to the inflammation site. When melanoma cells which overexpress 
chemokines (CXCL-1, CXCL-2 or CXCL-3) were injected subcutaneously into nude 
mice, more than 90% efficiency of tumor formation were observed compared with 7% in 
controls (Owen, Strieter et al. 1997). CXCL-12 increased colorectal tumor cell migration 
(Kollmar, Rupertus et al. 2007).  
Nitric oxide (NO) is produced by nitric oxide synthase (NOS). NO is important in 
vascular tone, neurotransmission and platelet aggregation. NO contributes to tumor 
development by stimulating cell proliferation and inducing DNA damage. Inducible NOS 
(iNOS) increased in human breast, prostate and gynecological cancers (Thomsen, Lawton 
et al. 1994; Thomsen, Miles et al. 1995; Aaltoma, Lipponen et al. 2001). In mouse skin, 
TPA treatment induces iNOS (Chun, Cha et al. 2004). In prostate cancer, iNOS 
expression level positively correlates with cell proliferation (Aaltoma, Lipponen et al. 
2001).  
NF-κB is a transcription factor and induces inflammatory (COX-2, iNOS, and 
TNF-α), anti-apoptotic (XIAP, Bcl-2), cell cycle regulatory (cyclin D1) and 
proangiogenic (vascular endothelial growth factor (VEGF) and angiopoietin) factors or 
inhibits apoptosis-inducing genes (p53 and Bad) (Kundu and Surh 2008). Deletion of 
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IKKβ, a kinase that release free NF- κB, in intestinal epithelial cells decreased tumor 




Cyclooxygenases are 72 kDa enzymes that convert arachidonic acid to PGG2 then 
to PGH2 (Howe, Subbaramaiah et al. 2001). PGH2 is further metabolized to produce 
various prostaglandin isomers (PGD2, PGE2, PGI2, thromboxane A2 (TXA2) and PGF2α) 
by specific isomerases (Figure 1-4) (Simmons 2004). 
There are two isoforms of COX. The COX-1 gene is on chromosome 9. COX-1, a 
constitutive COX, is expressed in most cells and tissues and maintains normal 
physiological functions. In the stomach, prostaglandins have protective roles by 
decreasing gastric secretion and increasing mucus production and by increasing 
bicarbonate in the duodenum. In the kidneys, vasodilator prostaglandins (PGD2, PGE2, 
and PGI2) regulate renal blood flow and renal vascular beds (Sanghi, MacLaughlin et al. 
2006). COX-1 is also expressed in neurons in the brain and in the uterus during 
pregnancy. Because platelets do not have nuclei, COX-2 cannot be induced. Therefore, 
COX-1 is important in platelets and leads to synthesis of TXA2 that induces platelet 
aggregation, vasoconstriction and vascular proliferation (DuBois, Abramson et al. 1998; 
Furstenberger, Krieg et al. 2006). 
COX-2, the inducible COX, is an immediate-early response gene that is not 
expressed in most normal tissues but is induced by mitogens, hypoxia, growth factors 
(epidermal growth factor (EGF), platelet derived growth factor (PDGF)), hormones, 
tumor promoters, polysaccharides, PGs and inflammatory stimuli, such as endotoxin,  
 
Figure 1-4. Arachidonic acid metabolism. Arachidonic acid is cleaved from 
phospholipids by phospholipase A2 (PLA2) and metabolized by cytochrome 
P450, lipoxygenases and cyclooxygenases. Cyclooxygenases convert 
arachidonic acid into PGH2 which is further metabolized to PGD2, PGI2, 
PGE2, PGF2α and TXA2 by specific isomerases. PGE2 binds four G protein 




cytokines (transforming growth factor-β (TGF-β), IL-1β, IL-2, interferon-γ, and TNF-α) 
(Breyer, Bagdassarian et al. 2001; Wang, Mann et al. 2005; Meric, Rottey et al. 2006). 
The COX-2 gene is on chromosome 1. COX-2 is important in inflammation, ovulation, 
kidney function, wound healing etc. In several types of tissues, COX-2 is also 
constitutively expressed; brain, kidney, bones, pancreatic β cells, spinal cord, ovaries, 
uterus, tracheal epithelial cells, small intestine and testicles (Sanghi, MacLaughlin et al. 
2006; Iezzi, Ferri et al. 2007). 
COX-2 is important in maintaining vascular function. PGI2 has both a 
vasodilatory function and an anti-platelet aggregation function (Sanghi, MacLaughlin et 
al. 2006). By comparison, COX-1 produces PGI2 for physiological homeostasis, but 
stress-induced COX-2 produces PGI2 to protect vessel walls from injury (Iezzi, Ferri et 
al. 2007). COX-2 is important in cardioprotection. PGI2 is the predominant COX-2 
product in endothelium. PGI2 inhibits platelet aggregation, induces vasodilation and 
inhibits proliferation of vascular smooth muscle cells (Fitzgerald 2004). Thus, it opposes 
the action of TXA2, which is produced by platelets.  
In the kidneys, prostaglandin levels are 1,000 fold higher than that of circulating 
levels. Prostaglandins are important in kidney physiology and modulate glomerular 
hemodynamics, tubular reabsorption of salt and water and rennin secretion (Sanghi, 
MacLaughlin et al. 2006). COX-2 is also important in the female reproductive system; 
specifically, in the rupture of follicle and implantation of the embryo (DuBois, Abramson 
et al. 1998). Therefore, COX-2 deficient mice die early due to renal problems and 
experience several difficulties in the female reproductive system: ovulation, fertilization 
and implantation (Dinchuk, Car et al. 1995; Morham, Langenbach et al. 1995; Lim, Paria 
et al. 1997). COX-2 is also important with regard to pain. COX-2 inhibitors reduce 
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inflammation and pain-related behavior in chemically-induced arthritis and inflammation 
in rats (Seibert, Zhang et al. 1994; Laird, Herrero et al. 1997).  
COX-2 is important in inflammatory responses. Proinflammatory agents (IL-1, 
TNF-α, lipopolysaccharide) induce COX-2 while anti-inflammatory cytokines (IL-4, and 
IL-13) decrease COX-2 levels (DuBois, Abramson et al. 1998). In a clinical study, 
celecoxib, a COX-2 inhibitor, improved rheumatoid arthritis conditions including 
morning stiffness and painful and tender joints (Lipsky and Isakson 1997). 
 
1.2.2 Importance of COX in tumor development 
There are extensive epidemiological studies that show that non-steroidal anti-
inflammatory drugs (NSAIDs), which are COX inhibitors, reduce risk of several types of 
cancer including colorectal (Brown 2005), esophageal, lung, breast, bladder and prostate 
(Pereg 2005; Rigas and Kashfi 2005). COX-2 is highly expressed in human cancers of 
the colon, gastric (Ristimaki, Honkanen et al. 1997), cervix, liver, pancreas (Howe, 
Subbaramaiah et al. 2001), esophagus, breast, bladder, lung and skin (Kagoura 2001; 
Subbaramaiah 2003).  
The importance of COX-2 in cancer has been studied with experimental animal 
models as well as in clinical studies. When APCΔ716 mice or Min mice, models for human 
familial adenomatous polyposis, were crossed with COX-2 knockout mice, the number of 
polyps and size of the polyps were significantly reduced (Oshima, Dinchuk et al. 1996; 
Chulada, Thompson et al. 2000). In a clinical study with familial adenoma polyposis 
patients, the administration of celecoxib for six months significantly reduced the number 
of colorectal polyps (Steinbach, Lynch et al. 2000). In three clinical studies with patients 
who had adenomas removed, celecoxib or rofecoxib reduced new adenoma formation 
(Arber, Eagle et al. 2006; Baron, Sandler et al. 2006; Bertagnolli, Eagle et al. 2006). In 
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breast cancer and lung cancer, COX-2 expression levels correlate with poor prognosis 
(Ristimaki, Sivula et al. 2002; Boland, Butt et al. 2004; Su, Shih et al. 2004). 
Administration of the NSAIDs aspirin, indomethacin or celecoxb reduced mammary 
tumor formation in rats (Howe, Subbaramaiah et al. 2001). Transgenic mice that 
overexpress COX-2 in mammary glands, developed mammary tumors (Liu, Chang et al. 
2001). In the skin, COX-2 is induced in UVB-exposed human keratinocytes, UVB 
irradiated human skin, human SCC, UVB irradiated mouse skin, UVB induced mouse 
papillomas and SCC, and DMBA/TPA induced mouse papillomas and SCC (Buckman, 
Gresham et al. 1998; Muller-Decker, Kopp-Schneider et al. 1998; Athar, An et al. 2001; 
An, Athar et al. 2002). In a DMBA/TPA skin carcinogenesis model, both COX-1 null 
mice and COX-2 null mice had reduced skin tumor development (Tiano, Loftin et al. 
2002). Application of COX inhibitors on skin reduced DMBA/TPA induced tumor 
formation as well as UV-induced tumor formation (Muller-Decker, Kopp-Schneider et al. 
1998; Fischer, Lo et al. 1999; Pentland, Schoggins et al. 1999). Consistent with these 
findings, transgenic mice that overexpress COX-2 in the epidermis develop more skin 
tumors than wild type mice (Muller-Decker, Neufang et al. 2002; Rundhaug, Pavone et 
al. 2007). Celecoxib, a COX-2 inhibitor, significantly suppressed lung metastasis when 
colon cancer cells were injected into the paws of mice and reduced fibroblast growth 
factor-2 induced neovascularization in the rat cornea (Masferrer, Leahy et al. 2000).  
 
1.2.3 Cyclooxygenase inhibitors 
Cyclooxygenase inhibitors are used to control pain, fever, and inflammation. The 
first NSAID to be developed was acetylsalicylic acid (Aspirin, Bayer Corp.). These 
NSAIDs have side effects on gastrointestinal tissues, inducing hemorrhagic gastric 
erosions and gastric ulcers, inducing or exacerbating duodenal ulcers, and damaging 
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distal regions of the small intestine. The causes of these side effects are systemic 
suppression of prostaglandin synthesis and topical irritation on the epithelium. Acidic 
NSAIDs migrate to epithelial cells and trap hydrogen ion, reducing hydrophobicity of the 
gastric mucus, thus allowing gastric acid and pepsin to damage the surface epithelium 
(Wallace 1997; Wolfe, Lichtenstein et al. 1999). The importance of reduced 
prostaglandin levels for gastrointestinal side effects of NSAIDs has been well 
documented. Parenteral or rectal NSAIDs still induced ulcers and PGE2 administration 
prevented indomethacin–mediated reduction of gastric blood flow (Wolfe, Lichtenstein et 
al. 1999). In addition, inhibition of COX-1, not COX-2, is responsible for these side 
effects. COX-1 is expressed in normal gastrointestinal tissue and endothelial cells. 
Gastric ulcers in mice had increased COX-2 mRNA and PG but no change in COX-1 
mRNA (Wallace 1997). Indomethacin (COX-1/COX-2 inhibitor) reduced PG synthesis 
but NS-398 (COX-2 specific inhibitor) did not reduce PG synthesis in gastrointestinal 
tissues. Thus, COX-1 is important in the cytoprotection of gastrointestinal tissue 
(Kargman, Charleson et al. 1996). The active site of COX-2 is about 20% larger than 
COX-1 (Smith, DeWitt et al. 2000). Therefore, COX-2 selective inhibitors were 
developed to reduce gastrointestinal side effects while retaining the same effect as 
NSAIDs on pain, fever, and inflammation.  
The COX-2 selective inhibitors, celecoxib and rofecoxib, had similar effects on 
rheumatoid arthritis inflammation and pain when compared to traditional NSAIDs 
(ibuprofen, diclofenac and naproxen) but celecoxib- and rofecoxib- treated patients had 
less gastrointestinal toxicity (Emery, Zeidler et al. 1999; Bombardier, Laine et al. 2000; 
Silverstein, Faich et al. 2000). Because COX-2 is upregulated in many tumors, these 
COX-2 specific inhibitors were studied for chemopreventive efficacy. In mouse models, 
COX-2 inhibitors showed effective reduction in tumor formation in colon, esophagus, 
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stomach, pancreas, prostate, tongue, skin and mammary (Oshima, Dinchuk et al. 1996; 
Fischer, Lo et al. 1999; Harris, Alshafie et al. 2000; Nakatsugi, Ohta et al. 2000; Buttar, 
Wang et al. 2002; Furukawa, Nishikawa et al. 2003; Rahme, Barkun et al. 2003; Wei, 
Morimura et al. 2003; Yamamoto, Kitayama et al. 2003; Bardou, Barkun et al. 2004; Hu, 
Yu et al. 2004; Narayanan, Narayanan et al. 2004). As previously mentioned, familial 
adenomatous polyposis patients who received celecoxib or rofecoxib had reduced number 
of colorectal polyps (Steinbach, Lynch et al. 2000; Higuchi, Iwama et al. 2003), however, 
they also had a higher incidence of cardiovascular side effects (Solomon, McMurray et 
al. 2005; Baron, Sandler et al. 2006). A possible explanation is a shift in the balance 
between PGI2 and TXA2. Rofecoxib and celecoxib suppressed PGI2 formation which is 
the predominant COX-2 product in endothelium. Since TXA2 is a COX-1 product in 
platelets, inhibition of COX-2 may increase the activity of TXA2 by removal of 
counteracting PGI2, without altering TXA2 levels. Thus, platelet aggregation and blood 
pressure might be increased, which could lead to increased risk of cardiovascular disease 
(Fitzgerald 2004). Therefore, it is likely that all COX-2 selective inhibitors might have 
similar cardiovascular side effects. 
 
1.3 PROSTAGLANDIN E2 
1.3.1 Prostaglandin E2 synthases (PGESs) 
PGESs convert PGH2 to PGE2. There are three isoforms of prostaglandin E2 
synthases. Cytosolic PGES, cPGES, is 23kDa and glutathione (GSH) is a cofactor for this 
enzyme. cPGES is constitutively expressed in several tissues and not induced by 
proinflammatory stimuli. mPGES-1 is a membrane bound form and also needs GSH as a 
cofactor. Proinflammatory stimuli induce mPGES-1, often along with induction of COX-
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2. Increased mPGES-1 expression is observed in several types of cancers. The third 
isoform, mPGES-2, does not require GSH as a cofactor. mPGES-2 is expressed in the 
brain, heart, skeletal muscle and kidneys. Unlike mPGES-1, mPGES-2 is expressed in 
several tissues and not induced during inflammation (Murakami and Kudo 2006). 
mPGES-1 and mPGES-2 are expressed in the tail skin, back skin, and in DMBA/TPA 
induced papillomas of NMRI mice (Neumann, Dulsner et al. 2007). 
 
1.3.2 Importance of PGE2 in tumor development 
Among the COX products, PGE2 levels have been found to be increased in human 
colon cancer (Rigas, Goldman et al. 1993) and human gastric cancer (Uefuji 2000). Also, 
PGE2 is the major arachidonic acid metabolite in cultured mouse skin epidermal cells 
(Fischer, Baldwin et al. 1988), human normal colorectal mucosa and human colorectal 
adenoma from familial adenomatous polyposis patients (Yang, Shields et al. 1998) and 
mouse mammary tissue (Chang 2004). In human keratinocytes, the PGE2 level is 
increased after UVB exposure (Buckman, Gresham et al. 1998). There are several studies 
that show that PGE2 is important in tumorigenesis. Celecoxib, a COX-2 selective 
inhibitor, inhibited human head and neck xenograft tumor growth with concomitant 
inhibition of PGE2 production by the tumor (Zweifel, Davis et al. 2002). Administration 
of PGE2 reversed NSAID-mediated suppression of intestinal tumor formation in Min 
mice (Hansen-Petrik 2002) and enhanced azoxymethane-induced colon cancer formation 
in rats (Kawamori, Uchiya et al. 2003). Injection of an antibody against PGE2 decreased 
intestinal tumor formation in Min mice (Hansen-Petrik 2002) and tumor growth in a head 
and neck squamous cell carcinoma xenograft model (Zweifel, Davis et al. 2002). PGE2 
abolished indomethacin–mediated growth inhibition in malignant keratinocytes 
(Thompson, Gupta et al. 2001).  
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PGE2 is known to exert its tumor promoting action through increasing 
proliferation, decreasing apoptosis, inducing angiogenesis, increasing invasion, and 
modulating immunosuppression (Wendum 2004; Wang, Mann et al. 2005). In colorectal 
carcinoma cells, PGE2 increased cell proliferation and cell motility via 
phosphatidylinositol-3-kinase (PI3K) (Sheng, Shao et al. 2001). In some tissues, PGE2 
increases cell proliferation through epidermal growth factor receptor (EGFR) via 
induction of EGFR ligand or shedding of EGFR ligand (Pai, Soreghan et al. 2002; Shao, 
Lee et al. 2003). In human colon cells, PGE2 treatment was found to reduce apoptosis 
through induction of Bcl-2 expression (Sheng, Shao et al. 1998). Treatment with PGE2 
reversed COX-2 inhibitor mediated suppression of capillary-like structure formation of 
rat aortic endothelial cells (Jones, Wang et al. 1999). PGE2 increased vascular endothelial 
growth factor and basic fibroblast growth factor in several different cells (Pai, Szabo et 
al. 2001; Trompezinski, Pernet et al. 2001; Chang, Liu et al. 2004; Spinella, Rosano et al. 
2004; Bradbury, Clarke et al. 2005; Taylor, Kim et al. 2008). Also, PGE2 promotes 
endothelial cell adhesion and spreading (Dormond, Bezzi et al. 2002). PGE2 promotes 
tumor growth by suppressing the immune system through inhibition of immune 
regulatory lymphokines, T- and B-cell proliferation and cytotoxic activity of natural killer 
cells and inducing IL-10 (Dempke, Rie et al. 2001).  
 
1.3.3 Metabolism of PGE2 
NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (PGDH) oxidizes the 
15-hydroxyl group of the prostaglandin molecule into an inactive keto group (Tai, Ensor 
et al. 2002). PGDH deficient mouse pups have about 2-fold higher PGE2 levels while 
TXA2 levels are similar, compared to wild type mouse pups (Coggins, Latour et al. 
2002). As bladder cancer progresses, expression of PGDH decreases and expression of 
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COX-2 increases, which would raise the level of PGE2 (Gee, Montoya et al. 2003). 
Expression of PGDH decreases in Min mouse adenomas, human breast cancer, lung 
carcinomas, and colon cancer relative to normal tissue (Backlund, Mann et al. 2005).  
 
1.3.4 PGE2 receptors 
PGE2 binds four subtypes of membrane receptors (EP1, EP2, EP3 and EP4) which 
are members of the family of seven transmembrane G-protein coupled receptors. 
Distribution of these receptors is tissue specific (Ushikubi, Hirata et al. 1995; Breyer, 
Bagdassarian et al. 2001).  
EP2 is coupled to Gαs and increases cAMP formation via activation of adenylate 
cyclase. cAMP binds to regulatory subunits of cAMP-dependent protein kinase (PKA), 
then the catalytic subunit is released and phosphorylates PKA substrates (Taylor, Kim et 
al. 2008). PKA phosphorylates cAMP-response element binding protein (CREB) on Ser 
133. Increased levels of cAMP translocate CREB co-activators (transducers of regulated 
CREB activity, TORC) from cytosol to nucleus. Together with Ser133 phosphorylated 
CREB, TORC facilitates recruitment of transcriptional coactivator CBP or p300 to CREB 
and increases transcription (Sands and Palmer 2008). PKA also phosphorylates GSK-3 
and activates β-catenin (Fujino, West et al. 2002). The binding affinity for EP2 is PGE1 > 
PGE2 > 16,16-dimethyl-PGE2 (synthetic PGE2 analog) > 11-deoxy PGE1 (synthetic PGE1 
analog) >> 1-hydroxy PGE1 > Butaprost (EP2 selective agonist) > AH-6809 (EP2 
antagonist) (Kiriyama, Ushikubi et al. 1997). EP2 is important in the female reproductive 
system in that female EP2 deficient mice have a reduced number of ovulations and a 
lower fertilization rate (Hizaki, Segi et al. 1999). EP2 is expressed in the lung (Ushikubi, 
Hirata et al. 1995) where it mediates the bronchodilating action of PGE2 (Sheller, 
Mitchell et al. 2000). In EP2 deficient mice salt-sensitive hypertension develops 
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(Kennedy, Zhang et al. 1999) and depression of blood pressure by PGE2 is impaired 
(Zhang, Guan et al. 2000).  
The importance of EP2 in cancer development has been shown in several different 
studies. When EP2 deficient mice were crossed with APCΔ716 mice, the number and size 
of intestinal polyp formation decreased (Sonoshita, Takaku et al. 2001). EP2 expression 
increased in TPA-treated mouse skin, DMBA/TPA-induced papillomas and carcinomas 
(Sung, He et al. 2006), chronic UV-irradiated mouse skin, UV-induced papillomas and 
carcinomas in SKH mice, human SCC (Lee, Kim et al. 2005), and human endometrial 
adenocarcinoma (Jabbour, Milne et al. 2001). EP2 deficient mice produced fewer tumors 
in the DMBA/TPA skin carcinogenesis model and EP2 overexpression produced more 
tumors in the DMBA/TPA skin carcinogenesis model with a concomitant effect on cell 
proliferation (Sung, He et al. 2005; Sung, He et al. 2006). When EP2 deficient mice were 
crossed with MMTV-COX-2 transgenic mice, which produce spontaneous mammary 
tumors, mammary hyperplasia and amphiregulin expression were reduced (Chang, Ai et 
al. 2005).  
There are three isoforms (EP3α, EP3β and EP3γ) of EP3 in the mouse, and seven 
isoforms in human. All mouse EP3 are coupled to Gαi and inhibit adenylate cyclase and 
decrease cAMP levels. Interestingly, EP3γ is also coupled to Gαs. Activation of EP3 also 
increases intracellular calcium levels by activation of phospholipase C (PLC) through the 
Gβγ subunit (Hatae, Sugimoto et al. 2002). The binding affinity of EP3 is sulprostone 
(PGE2 analog, EP3 agonist)> PGE2 > PGE1 > 11-deoxy PGE1 > 16,16-dimethyl PGE2 > 
17-phenyl PGE2 (EP1, EP3 agonist) (Kiriyama, Ushikubi et al. 1997). In EP3 deficient 
mice, PGE2 failed to induce fever (Ushikubi, Segi et al. 1998), acid did not induce 
bicarbonate ion secretion in the duodenum (Takeuchi, Ukawa et al. 1999), PGE2 reduced 
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blood pressure more effectively (Audoly, Tilley et al. 1999), and indomethacin-mediated 
concentration of urine was reduced (Fleming, Athirakul et al. 1998).  
There are several literature reports that show EP3 is not important in 
carcinogenesis. When EP3 deficient mice were crossed with APCΔ716 mice, there was no 
difference in intestinal polyp formation (Sonoshita, Takaku et al. 2001). In chronic UVB-
irradiated mouse skin, EP3 expression is not detectable. In UVB induced mouse 
papillomas and SCC, EP3 expression was very low (Lee, Kim et al. 2005). In human skin 
SCC, EP3 expression was not changed compared to adjacent tissue (Lee, Kim et al. 
2005). EP3 deficient mice produced a similar number of DMBA/TPA-induced skin 
tumors with similar incidence to wild type mice (Sung, He et al. 2005). In contrast, EP3 
deficient mice were found to produce less VEGF and implanted sarcoma growth was also 
reduced (Amano, Hayashi et al. 2003). 
EP4 is also coupled to Gαs and increases cAMP formation. Similar to EP2, 
activation of EP4 induces activation of PKA, resulting in phosphorylation of CREB, 
GSK-3 and activation of β-catenin. In addition, EP4 is coupled to Gαi which decreases 
cAMP and activates PI3K. PI3K can activate Akt which phosphorylates CREB and GSK-
3. Also, PI3K can activate Erk (Regan 2003; Fujino, Salvi et al. 2005). The binding 
affinity of EP4 is PGE2 > PGE1 >> 11-deoxy-PGE1 > 16,16-dimethyl PGE2 > > 1-
hydroxy PGE1 (Kiriyama, Ushikubi et al. 1997). EP4 is expressed in human and mouse 
heart, lung, thymus, spleen, ileum and skin (Ushikubi, Hirata et al. 1995; Lee, Kim et al. 
2005). In EP4 deficient mice, ductus arteriosus, an artery that allows for bypassing the 
fetal pulmonary system, fails to close. As a result, 95% of EP4 deficient newborn mice 
die after birth (Nguyen, Camenisch et al. 1997). In mice, PGE2 enhances bone resorption 
through EP4 (Miyaura, Inada et al. 2000).  
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The role of EP4 in cancer has also been studied. EP4 deficient mice were found to 
produce fewer azoxymethane (AOM)-induced aberrant crypt foci. The EP4 antagonist 
ONO-AE2-227 reduced AOM-induced aberrant crypt foci formation and intestinal polyp 
formation in Min mice (Mutoh, Watanabe et al. 2002). The EP4 agonist 1-hydroxy PGE1 
abolished indomethacin-mediated growth inhibition in a mouse adenocarcinoma cell line 
(Pozzi, Yan et al. 2004). The administration of EP4 antagonist ONO-AE3-208 reduced 
Lewis lung carcinoma cell metastasis in mouse (Yang, Huang et al. 2006). Mouse 
mammary tumor cell lines treated with the EP4 antagonists AH23848 and ONO-AE3-208 
resulted in a reduction in lung metastasis (Ma, Kundu et al. 2006). 
 
1.4 EP1 RECEPTOR FOR PGE2 
1.4.1 EP1 
EP1 is composed of 405 amino acids with an estimated molecular weight of 
43kDa. At the N terminal, 3 possible N-glycosylation sites are present. There are two 
possible phosphorylation sites for PKA in the first and third intracellular loop and one 
possible phosphorylation site for protein kinase C (PKC) in the third intracellular loop of 
the receptor. The dissociation constant for PGE2 is 21 nM. The binding affinity for EP1 is 
in the following order: 17-phenyl PGE2 > PGE2 > iloprost (a stable prostacyclin 
analogue) = sulprostone > PGE1 (Watabe, Sugimoto et al. 1993). 
EP1 is expressed in the mouse lung, kidney, brain, bladder, blood vessel, 
sebaceous gland and in the epidermis of the skin (stratum corneum, stratum granulosum 
and basal layer) and human skin (Watabe, Sugimoto et al. 1993; Ushikubi, Hirata et al. 
1995; Lee, Kim et al. 2005; Matsuoka, Furuyashiki et al. 2005; Tober, Wilgus et al. 2006; 
Neumann, Dulsner et al. 2007; Wang, Momota et al. 2008). In normal human epidermis, 
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EP1 is located in the plasma membrane and cytosol in the basal layer and spinous layers 
of the skin as well as in primary cultures of human keratinocytes (Konger, Billings et al. 
2005).  
EP1 is a G-protein coupled rhodopsin-type receptor as are other PGE2 receptors. 
However, the G protein is pertussis toxin-insensitive. After EP1 activation, extracellular 
calcium influxes through the voltage-independent, Mn2+ impermeable calcium channel. 
Calcium is also released from intracellular stores in a PLC-dependent manner (Figure 1-
5). Phosphorylation of EP1 by PKC reduced PGE2 binding to EP1 and PGE2-mediated 
intracellular calcium increase. Thus, PKC phosphorylation desensitizes EP1 by 
dissociation of EP1 with G-protein. In EP1 expressing Chinese hamster ovary cells, EP1 
mRNA expression was reduced one day after treatment with TPA, a potent PKC activator 
(Katoh, Watabe et al. 1995). However, in human erythroleukemia cells, EP1 mRNA is 
induced two days after TPA treatment (Funk, Furci et al. 1993). 
In osteoblast cells, EP1 activated PKCα and Src, resulting in increased fibronectin 
expression (Tang, Yang et al. 2005). In human cholangiocarcinoma cells, PGE2 promoted 
cell growth and invasion through EP1 receptor activated Src/EGFR/Stat3/Akt signaling 
(Han and Wu 2005; Han, Demetris et al. 2006). EP1-mediated Erk activation was shown 
in non-small cell lung cancer cells (Krysan, Reckamp et al. 2005).   
EP1 agonists also induce COX-2 with concomitant PGE2 increases in mouse 
osteoblastic cells. EP1 also increased c-fos and c-jun mRNA. However, antisense c-fos or 
c-jun did not affect 17-phenyl-2 trinor PGE2-mediated COX-2 mRNA induction (Suda, 
Tanaka et al. 2000).  
Interestingly, EP1 is very important in the brain. EP1 antagonist SC51089 
protected against mouse brain injury induced by middle cerebral artery occlusion (Abe, 
Kunz et al. 2008; Zhou, Qian et al. 2008). EP1 deficient mice show increased  
 
Figure 1-5. Second messenger system of EP1 receptor. After EP1 activation extracellular 
calcium influxs through calcium channel. Activation of phospholipase C 
release IP3 (inositol 1,4,5-trisphosphate) which releases calcium from 




aggressiveness when they are stressed, along with reduced social interaction (Matsuoka, 
Furuyashiki et al. 2005). In EP1 deficient mice, PGE2 failed to induce bicarbonate ion  
secretion in the stomach (Takeuchi, Aihara et al. 2006). In the bladder, EP1 mediates 
micturition in mice (Wang, Momota et al. 2008). EP1 is also important in inflammation. 
In Leydig cell progenitors, EP1 mediates IL-1β expression (Walch, Clavarino et al. 
2003). EP1 deficient mice are insensitive to pain and EP1 receptor antagonist, ONO-
8711, suppressed mechanical hyperalgesia (Omote, Yamamoto et al. 2002). In EP1 
deficient mice, systolic blood pressure is also reduced (Stock, Shinjo et al. 2001). 
 
1.4.2 Importance of EP1 in tumor development 
The importance of EP1 receptors in carcinogenesis has been studied using diverse 
models. EP1-deficient mice developed fewer aberrant crypt foci, preneoplastic lesions, 
after AOM treatment. EP1 antagonists, ONO-8711 and ONO-8713, in the diet reduced 
aberrant crypt foci formation in mouse. In Min mice, ONO-8711 administration reduced 
intestinal polyp development (Watanabe, Kawamori et al. 1999; Watanabe, Kawamori et 
al. 2000). In EP1 deficient mice, tumor incidence, tumor multiplicity and tumor volume 
were decreased in the AOM-induced colon carcinogenesis model. In these tumors, a 
lower cell proliferation index and higher apoptotic index were observed (Kawamori, 
Kitamura et al. 2005). After UV treatment of mice, the number of EP1 positive cells was 
increased in skin (Tober, Wilgus et al. 2006). Thirty weeks of UV exposure increased 
EP1 expression extensively. In UVB-induced mouse papillomas and SCCs and human 
SCCs, EP1 mRNA expression and protein levels were increased 2 ~ 10 fold (Lee, Kim et 
al. 2005; Tober, Thomas-Ahner et al. 2007). Topical application of ONO-8713, an EP1 
antagonist, reduced UV-induced skin tumor formation and UV-induced inflammatory 
index, such as skin thickness, myeloperoxidase activity, PGE2 content and the number of 
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p53 positive cells (Tober, Wilgus et al. 2006). Also 17-phenyl trinor PGE2 (EP1/EP3 
agonist) abolished indomethacin–mediated growth inhibition in malignant keratinocytes 
that do not express EP3 (Thompson, Gupta et al. 2001). The EP1 antagonists, SC51089 
and AH6809, suppressed cell proliferation about 30~50% in human glioma cells. 
SC51089  injected i.p. suppressed human glioma cell xenograft growth by about 50% 
(Matsuo, Yoshida et al. 2004). EP1 is not expressed in normal mouse mammary gland 
but highly expressed in mammary tumors. ONO-8711 administration inhibited 2-amino-
1-methyl-6-phenylimidazo[4,5-b]pyridine induced mammary tumor development 
(Kawamori, Uchiya et al. 2001). In rat hepatocytes, treatment with 17-phenyl-trinor-
PGE2 and sulprostone, EP1 agonists, increased DNA synthesis and the number of nuclei 
in a PLC-dependent manner. (Kimura, Osumi et al. 2001).  
EP1 is also important in lymphangiogenesis. In human lung cancer cells, 17-
phenyl trinor PGE2, an EP1/EP3 agonist, significantly induced VEGF-C mRNA and 
protein, a lymphangiogenic factor. SC19220, an EP1 antagonist or an EP1 antisense 
oligonucleotide effectively inhibited PGE2-mediated VEGF-C mRNA and protein 
induction. EP1-mediated VEGF-C induction in these cells was mediated through Src and 
Her2/Neu activation (Su, Shih et al. 2004). In human breast cancer cells, EP1 receptor 
antagonist treatment significantly suppressed VEGF-C protein production (Timoshenko, 
Chakraborty et al. 2006). 
Tumor cells evade the immune system by upregulation of Fas ligand which is 
associated with apoptosis of lymphocytes. Inhibition of EP1 by siRNA successfully 
inhibited PGE2-mediated upregulation of Fas ligand in colon tumor cells (O'Callaghan, 
Kelly et al. 2008). 
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1.5 HYPOTHESIS AND THE SPECIFIC AIMS  
Cancer was the second leading cause (27%) of death in the U.S.A. in 2005. As 
mentioned above, NSAIDs reduce the risk of several types of cancer. The gastro-
intestinal side effect of NSAIDs led to the development of COX-2 specific inhibitors. 
However, COX-2 inhibitors increase the risk of cardiovascular disease. Thus, the 
downstream effectors of COX-2 could be the next targets for chemoprevention. PGE2 is 
an important mediator of COX-2-mediated cancer promoting action and EP1 is one of the 
PGE2 receptors. EP1 is expressed in mouse skin epidermis as well as in human skin 
epidermis (Konger, Billings et al. 2005; Lee, Kim et al. 2005). EP1 expression increases 
in chronically UV-irradiated mouse skin and UVB-induced papilloma and SCC. Also, 
EP1 is the most highly expressed PGE2 receptor in mouse and human nonmelanoma skin 
cancer (Lee, Kim et al. 2005). Topical application of an EP1 antagonist reduces UV-
induced skin tumor development (Tober, Wilgus et al. 2006). The importance of EP1 in 
carcinogenesis has been studied in the colon, tongue, and mammary in vivo tumor 
models. Therefore, it is hypothesized that activation of EP1 contributes to skin tumor 
development by mediating the tumor promoting action of PGE2 in skin 
carcinogenesis. Following are the specific aims designed to test the hypothesis.  
1. Determine whether changes in EP1 expression and activation alter skin 
tumor development.  







Chapter 2 Materials and methods 
2.1 MATERIALS  
2.1.1 Materials 
TRI-reagent (Molecular Research Center,Inc., Cincinnati, OH), RETROscript kit 
(Ambion, Austin, TX), RNeasy Mini kit (Qiagen, Valencia, CA), universal master mix 
(Applied Biosystems, Foster City, CA), EP1 specific primers and probes (Applied 
Biosystems), 1Kb DNA ladder (Invitrogen Corporation, Carlsbad, CA), QIAEX II Gel 
Extraction kit (Qiagen), PerfectHyb plus solution (Sigma Aldrich, St Louis, MO), [γ-
32P]d-CTP (Perkin Elmer, Waltham, MA), Random Primed DNA Labeling Kit (Roche 
Applied Science, Indianapolis, IN), SDS (Bio-Rad Laboratories, Hercules, CA), sodium 
chloride (Fisher Scientific), sodium citrate (Sigma Aldrich), Signal Transduction 
Pathway Finder PCR Array (SABiosciences, Frederick, MD), acetone (Fisher Scientific, 
Pittsburgh, PA), magnesium chloride (Sigma Aldrich), EGTA (Sigma Aldrich), glycerol 
(Fisher Scientific), Triton X-100 (Sigma Aldrich), Mouse TNF–α Quantikine (R &D 
Systems, Minneapolis, MD), 5-bromo-2’-deoxyuridine (BrdU) (Sigma Aldrich), anti-
BrdU antibody (BD Biosciences, San Jose, CA) biotinylated rabbit anti-mouse IgG 
(Accurate Chemical Company, Westbury, NY), streptavidin peroxidase (BioGenex, San 
Ramon, CA), Ki-67 antibody (DAKO, Carpinteria, CA), DMBA (Sigma Aldrich), TPA 
(LC Laboratories, Woburn, MA), dithranol (Sigma Aldrich), EDTA (Sigma Aldrich), 
Tris (Fisher Scientific), Tween 20 (Sigma Aldrich), protease inhibitor cocktail tablet 
(Roche Applied Science), polyvinylidene fluoride (PVDF) membrane (Thermo-Fisher, 
Waltham, MA), BCA kit (Bio-Rad, Richmond CA), 30% acrylamide (ProtoGel, National 
Diagnostics USA, Atlanta, GA), Benchmark prestained ladder (Invitrogen Corporation), 
enhanced chemiluminescence (ECL) Plus (GE Healthcare, Piscataway, NJ), Blue Lite 
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Autorad film (ISC Bioexpress, Kaysville, UT), COX-2 antibody (Cayman Chemical Co., 
Ann Arbor, MI), PKC-α antibody (Santa Cruz Biotechnology, Inc., Santa Cruz, CA),  β-
actin antibody (Santa Cruz Biotechnology, Inc.), EGFR antibody (Cell Signaling 
Technology, Danvers, MA), p-EGFR antibody (Cell Signaling Technology), Stat3 
antibody (Cell Signaling Technology), p-Stat3 antibody (Cell Signaling Technology), 
CYP1B1 (Santa Cruz Bio Technology), benzo[a]pyrene (B[a]P) (Sigma Aldrich), 3H 
B[a]P (American Radiolabeled Chemicals, Inc., St. Louis, MO), phenol (Fisher 
Scientific), chloroform (Fisher Scientific), isoamyl alcohol (Sigma Aldrich) and ras-
activation assay kit (Upstate Inc., Waltham, MA) were used.  
 
2.1.2 Animals 
Wild type female FVB mice and SKH mice at the age of 3-4 weeks were 
purchased from Harlan (Indianapolis, IN). EP1 knockout mice on a C57BL/6 background 
were obtained from Dr. Shuh Narumiya, Kyoto University, Japan and backcrossed to 
FVB and SKH more than five times. For experiments, female mice at 6-9 weeks of age 
were used. Mice were maintained at Science Park and housed in an air conditioned (22 ± 
1° C at 50% humidity) facility that is accredited by the Association for Assessment and 
Accreditation of Lab Animal Care Accredited. 
 
2.2 METHODS 
2.2.1 Quantitative real-time polymerase chain reaction analysis 
Epidermal scrapes were collected from three mice at each time point after the last 
treatment. Total RNA was extracted from epidermal scrapes, papillomas and carcinomas 
with TRI-reagent (Molecular Research Center, Inc.) and purified through RNeasy 
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minicolumns (Qiagen). One microgram of total RNA was reverse transcribed with 
random decamers using RETROscript kit (Ambion) in 20 µl reactions, then diluted to 40 
µl with tRNA. For PCR reactions, 2 µl (50 ng starting RNA) were used per assay and 
each sample was analyzed in triplicate. PCR was carried out in a 25 µl volume with 1X 
universal master mix (Applied Biosystems). Proprietary 20X EP1 specific primers and 
probes (Applied Biosystems) were used. C-Ha-ras was used as a control gene to compare 
expression; forward primer (300 nM, 5’-CTTAGACACAGCAGGTCAAGAAGAGT-
3’), reverse primer (300 nM, 5’-TTGATGGCAAATACACAGAGGAA-3’) and probe 
(100 nM, 5’FAM-CCAGTACATGCGCACAG-MGB). Reaction condition was 50° C for 
2 min, 95° C for 10 min, followed by 40 cycles of 95° C for 15 s and 60° C for 1 min. To 
verify lack of contaminating DNA in samples, control samples were processed without 
reverse transcriptase. ABI 7700 (Applied Biosystem) was used for quantitative real time 
PCR analysis. Relative quantification method was used to calculate relative fold changes.  
 
2.2.2 Production of BK5.EP1 transgenic mice 
Murine EP1 cDNA was excised from pBluescript-EP1 (obtained from Dr. 
Yukihiko Sugimoto, Kyoto University, Japan) by digestion with EcoR I enzyme. Klenow 
DNA polymerase was used to blunt end the cDNA. The pBK5.EP1 construct was made 
by ligating the mouse EP1 cDNA into pBK5, which contains the bovine keratin 5 
promoter, a β-globin intron and SV40 poly A. The orientation of the construct was 
checked by a series of diagnostic restriction digestions. The BK5.EP1 transgene construct 
was excised from the pBK5.EP1 plasmid by digestion with Kpn I enzyme and separated 
in 0.7% agarose gel. The 8.2 kb fragment was isolated from the gel with a QIAEX II Gel 
Extraction kit (Qiagen). The BK5.EP1 transgene was microinjected into the pronucleus 
of fertilized FVB embryos. After overnight incubation, those embryos were transferred to 
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pseudopregnant mice. The injection procedures were carried out by the Science Park 
Transgenic Animal Facility Core. Transgenic mice were genotyped by Southern blot 
using the mouse EP1 cDNA.  
 
2.2.3 Southern blot analysis 
Genomic DNA was isolated from tail and 5 µg DNA was digested with AlwNI 
enzyme. Digested DNA was separated on 0.7% agarose gel then transferred onto nylon 
membrane. EP1 cDNA was labeled with [γ-32P]d-CTP using Random Primed DNA 
Labeling Kit (Roche Applied Science, Indianapolis, IN) and hybridized with the blot 
overnight. The blot was washed twice with low stringency wash solution (0.1% SDS/0.3 
M NaCl/30 mM sodium citrate) for 15 min each at room temperature and high stringency 
wash solution (0.1 % SDS/15 mM NaCl/0.15 mM sodium citrate) twice for 30 min at 60° 
C. The blot was exposed to X-ray film at -80° C. 
 
2.2.4 Northern blot analysis 
Total RNA was extracted from the epidermis of BK5.EP1 transgenic mice and 
wild type mice with TRI-reagent (Molecular Research Center, Inc.). Ten microgram of 
total RNA was separated on a 1% agarose gel containing formaldehyde and transferred 
onto nylon membrane. EP1 cDNA was labeled with [γ-32P]d-CTP using Random Primed 
DNA Labeling Kit (Roche Applied Science). The nylon membrane was incubated with 
the labeled EP1 cDNA at 65° C overnight. Unincorporated probe was removed by 
incubation of the blot with low stringency wash solution (0.1% SDS/0.3 M NaCl/30 mM 
sodium citrate) twice for 15 min each at room temperature and with high stringency wash 
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solution (0.1% SDS/15 mM NaCl/0.15 mM sodium citrate) twice for 30 min at 60° C. 
The blot was exposed to X-ray film at -80° C .  
 
2.2.5 Microarray  
Epidermal scrapes were collected from 3 mice for each group. Total RNA was 
extracted with TRI-reagent (Molecular Research Center, Inc.) and purified through 
RNeasy minicolumns (Qiagen). RNA from three mice was pulled together. Signal 
Transduction Pathway Finder PCR Array (SABiosciences) was used according to the 
manufacturer’s instructions.   
 
2.2.6 TNF – α  
Total protein was extracted from epidermis 2.5 hr after acetone (200 µl) or TPA 
(2.5 µg/200 µl acetone) treatment with lysis buffer (50 mM HEPES, 150 mM sodium 
chloride, 1.5 mM magnesium chloride, 1 mM EGTA, 10% glycerol, 1% Triton X-100). 
TNF–α level was determined by quantitative sandwich enzyme immunoassay technique 
according to the manufacturer’s instructions (Quantikine Mouse Immunoassay, R & D 
Systems).  
 
2.2.7 Bromodeoxyuridine (BrdU) incorporation 
Groups of 3 mice were used. Dorsal hair was shaved 2 days prior to treatment. 
BrdU (0.1 mg/g body weight) was injected intraperitoneally 17 hours after the last 
treatment. One hour after BrdU injection, the mice were euthanized, then dorsal skin was 
removed and fixed in 10% formalin. The Histology and Tissue Processing Core at the 
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University of Texas M. D. Anderson Cancer Center embedded the formalin fixed samples 
in paraffin and immunostained for BrdU.  
Briefly, 4 μm thick paraffin sections were deparaffinized and gradually hydrated. 
To block endogenous peroxidase activity, the sections were incubated with 0.3% H2O2 
for 30 min. After three washes with phosphate buffered saline (PBS), sections were 
incubated with 10 mM citrate buffer, pH 6.0 for 15 min in a microwave oven to retrieve 
antigen. Following three washes with PBS, sections were incubated with 10% rabbit 
serum for 30 min, followed by incubation for 1.5 hr with a monoclonal mouse anti-BrdU 
antibody (BD Biosciences) at 1:500 dilution. After washing with PBS, sections were 
incubated with biotinylated rabbit anti-mouse IgG (Accurate Chemical Company) at 
1:250 dilution for 15 min and followed by washing with PBS. Sections were incubated 
with streptavidin peroxidase (BioGenex) for 30 min. 3,3’-Diaminobenzidine 
tetrahydrochloride was used as a chromogen and sections were counterstained with 
hematoxylin. BrdU positive and negative basal cells in the interfollicular region of the 
epidermis were counted under a microscope (200 X). At least 1500 total basal cells were 
counted for each sample.  
 
2.2.8 Measurement of epidermal thickness 
Groups of 3 mice were used. Dorsal hair was shaved 2 days prior to treatment. 
Eighteen hours following the last treatment, dorsal skin was removed and fixed in 10% 
formalin. The Histology and Tissue Processing Core at the University of Texas M. D. 
Anderson Cancer Center embedded the formalin fixed samples in paraffin and performed 
hematoxylin and eosin (H&E) staining. An imaging system (Nikon ACT-1, Nikon, 
Melville, NY) was used to measure epidermal thickness. The on-screen thicknesses of the 
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epidermis were obtained for at least 50 points of interfollicular region per sample. A 
magnification factor (X650) was used to calculate the actual thickness of epidermis. 
 
2.2.9 DMBA/TPA skin carcinogenesis protocol 
Groups of 28 female BK5.EP1 transgenic mice and 28 wild type mice at 6-9 
weeks of age were used. Dorsal hair of the mice was shaved 2 days prior to initiation. 
Initiation was achieved by a single topical application of DMBA (100 μg/200 μl 
acetone). Two weeks after initiation, TPA (2.5 μg/200 μl acetone) was applied topically 
twice weekly for 20 weeks. Tumors were counted weekly to calculate tumor incidence 
(percentage of mice bearing tumors) and multiplicity (average number of tumors per 
mouse).  
 
2.2.10 DMBA/Anthralin skin carcinogenesis protocol 
Groups of 32 BK5.EP1 transgenic mice and 32 wild type mice were used. Dorsal 
hair of the mice was shaved 2 days prior to initiation. Initiation was achieved by a single 
application of DMBA (100 μg/200 μl acetone). Two weeks after initiation, anthralin (100 
nM/200 μl acetone) was applied once weekly. Tumors were counted every week to 
calculate tumor incidence and multiplicity.  
 
2.2.11 UV skin carcinogenesis protocol 
Groups of 26 female BK5.EP1 transgenic mice and wild type mice at 6-9 weeks 
of age were used. An UV apparatus (Fischer, Conti et al. 2003) providing 80% UVB and 
20% UVA was used. An established UV protocol (Noonan, Otsuka et al. 2000) was 
employed with modification. Dorsal hair of the mice was shaved just prior to UV 
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treatment. For the first 4 weeks, mice were treated with 220 mJ/cm2 three times a week. 
The dose was increased every two weeks to 260 mJ/cm2, 320 mJ/cm2, 340 mJ/cm2, and 
maintained at 360 mJ/cm2 for 24 weeks. Tumors were counted every week to calculate 
tumor incidence and multiplicity.  
Groups of 25 female EP1 deficient mice on SKH background and wild type SKH 
mice at 6-9 weeks of age were used. The above described apparatus providing 80% UVB 
and 20% UVA was used. For the first week, mice were treated with 90 mJ/cm2 three 
times a week. Every week, the dose was increased 10% up to 175 mJ/cm2, then 
maintained at the 175mJ/cm2 dose. Tumors were counted every week to calculate tumor 
incidence and multiplicity.  
 
2.2.12 DMBA-only skin carcinogenesis protocol 
Groups of 32 female BK5.EP1 transgenic mice and 32 female wild type mice 
were used. Dorsal hair of the mice was shaved 2 days prior to initiation. Initiation was 
achieved by application of DMBA (400 μg/200 μl acetone). Tumors were counted every 
week to calculate tumor incidence and multiplicity. 
 
2.2.13 Western blot analysis 
At specified times after treatment, total protein was extracted from epidermis with 
modified RIPA buffer (150 mM NaCl, 0.005% Triton X-100, 0.2 mM EDTA (pH 8.0) in 
50 mM Tris, pH 7.5). Fifty microgram of protein was denatured by incubation at 95° C 
for 10 min and separated on 7-10% SDS-polyacrylamide gel by electrophoresis and 
transferred onto polyvinylidene difluoride membranes. The blot was incubated for 1 hr in 
5% non-fat milk solution in Tris-buffered saline to block nonspecific binding. A specific 
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primary antibody was incubated for 1 hr at room temperature. The blot was washed three 
times with 0.1% Tween 20 in Tris-buffered saline for 5 min each. Horseradish 
peroxidase-conjugated secondary antibody was incubated for 1 hr at room temperature. 
The blot was washed with 0.1% Tween 20 in Tris-buffered saline for 5 min each and 
incubated with chemiluminescent substrate and exposed to autoradiography film.  
 
2.2.14 B[a]P-DNA adduct formation 
Groups of 4 mice were used. Dorsal hair was shaved 2 days prior to treatment. 
200 nmol, 200 μCi of 3H-B[a]P in 200 μl of acetone was applied to each mouse back. 
Fifteen hours after the 3H-B[a]P treatment, epidermis was scraped into 0.75 M guanidine 
isothiocyanate and homogenized by passing through a syringe 10 times. The epidermal 
scrape was dialyzed in 0.15 M sodium chloride, 0.01 M sodium citrate for 2 days. To 
remove protein, proteinase K was incubated with sample at 55° C for 3 hours. Sample 
DNA was extracted with water-saturated phenol. To remove RNA, 10 μl of RNase A was 
incubated with sample at 37° C for 30 min. DNA was extracted with 
phenol:chloroform:isoamyl alcohol (25:24:1), then chloroform:isoamyl alcohol (24:1). 
DNA was precipitated with ethanol then incubated -80° C for 5 min. Precipitated DNA 
was washed with cold 75% ethanol. DNA pellets were dissolved in 0.01 M Tris, 0.01 M 
MgCl2 solution, then the amount of DNA was quantitated by ultraviolet 
spectrophotometer. Twenty microgram of DNA aliquots were used to measure B[a]P-
DNA adduct in a scintillation counter.  
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2.2.15 Ras activation assay  
Ras activity was measured by a ras activation assay kit (Upstate Inc.). Briefly, 
total protein was extracted from epidermis with magnesium lysis buffer. Ten microgram 
of the Ras assay reagent was incubated with 500 µg of protein extract overnight at 4° C. 
After centrifugation, beads were washed 3 times with the magnesium lysis buffer then 
resuspended in sample buffer and boiled for 5 min. After centrifugation, supernatant was 
loaded onto a 12% SDS-polyacrylamide gel, separated by electrophoresis, then 
transferred onto polyvinylidene difluoride membranes. The blot was incubated for 2 hr in 
3% non-fat milk solution in Tris-buffered saline to block nonspecific binding. Anti-ras 
antibody was incubated overnight at 4° C. The blot was washed three times with 0.05% 
Tween 20 in Tris-buffered saline for 5 min each. Horseradish peroxidase conjugated anti-
mouse antibody was incubated for 1 hr at room temperature. The blot was washed with 
0.05% Tween 20 in Tris-buffered saline for 5min each and incubated with 
chemiluminescent substrate and exposed to autoradiography film.  
 
2.2.16 Statistical analysis 
Data are shown as the mean ± standard deviation. To determine statistical 
differences between means, independent t-test, independent proportions test, two-way 






Chapter 3 Results 
3.1 EP1 MRNA EXPRESSION AFTER TUMOR PROMOTER TREATMENT AND IN 
TUMORS  
EP1 mRNA levels in the mouse epidermis and skin tumors were measured with a 
quantitative real-time PCR method. After a single application of TPA, the EP1 mRNA 
level was increased about 2-fold after 6 hours and returned to slightly below normal 
levels after 18 hours. Four treatments of TPA produced similar patterns as one TPA 
treatment. In papillomas and carcinomas from a DMBA/TPA protocol, EP1 mRNA also 
increased 11-fold and 7-fold respectively (Figure 3-1A). 
After a single exposure to UV, EP1 mRNA levels increased about 2-fold after 6-
hours and this elevated level was maintained for 18 hours. Twenty-four hours after UV 
treatment, the EP1 mRNA level returned to the control level. Seven exposures to UV 
increased EP1 mRNA level by 18 hours and this elevated level returned to control level 
after 48 hours. In UV-elicited papillomas and carcinomas, EP1 mRNA increased 3-fold 
and 4-fold respectively (Figure 3-1B). Thus, increased EP1 mRNA levels in tumor 
promoter-treated epidermis and tumors imply increased EP1 signaling. Therefore, EP1 
could be one of the important PGE2 receptors contributing to skin carcinogenesis.  
 
3.2 EFFECT OF EP1 DEFICIENCY ON DMBA/TPA SKIN CARCINOGENESIS  
To examine the effect of EP1 deficiency on skin tumor development, a 
DMBA/TPA skin carcinogenesis protocol was used with EP1 deficient mice and wild 
type mice. Both wild type mice and EP1 deficient mice produced the first tumor at 8 
weeks of promotion. Starting at week 8 of promotion, the EP1 deficient mice produced 





Figure 3-1. EP1 mRNA expression after TPA or UV treatment and in tumors. A. EP1 
mRNA levels in TPA-treated epidermis and DMBA/TPA-induced tumors. 
Dorsal hair of FVB mice was shaved at least two days before TPA (2.5 
µg/200 µl acetone) treatment. Epidermal scrapes were collected at the time 
points shown after the last TPA treatment. The EP1 mRNA level was 
determined by quantitative real-time PCR. Ace, acetone (200 µl) treatement; 
1X TPA, one TPA (2.5 µg/200 µl acetone) treatment; 4X TPA, mice were 
treated with TPA (2.5 µg/200 µl acetone) every three days for 4 treatments; 
Pap, papilloma from DMBA-TPA tumor study of FVB mice; Car, 
carcinoma from DMBA-TPA tumor study of FVB mice. Three mice were 
used at each time point and three papilloma and five carcinoma samples 
were used. Data are expressed as the fold change in EP1 mRNA levels 
relative to acetone-treated epidermal levels. ** p< 0.01, independent t test, 
compared to acetone treated group. B. EP1 mRNA levels in UV-exposed 
epidermis and UV-induced tumors. SKH mice were exposed to UV. 
Epidermal scrapes were collected at the time points shown after the last UV 
exposure. The EP1 mRNA level was determined by quantitative real-time 
PCR. Cont, control, non-irradiated epidermis; 1X UV, one UV (120mJ/cm2) 
exposure; 7X UV, 7 exposures to UV, 3 times per week at 90 mJ/cm2 three 
times, 120 mJ/cm2 three times, and one treatment of 140 mJ/cm2 ; Pap, 
papilloma from UV tumor study of SKH mice; Car, carcinoma from UV 
tumor study of SKH mice. Three mice were used at each time point and 
three papilloma and four carcinoma samples were used. Data are expressed 
as the fold change in EP1 mRNA levels relative to non-irradiated epidermal 
levels. * p< 0.05, independent t test, compared to control. ** p< 0.01, 
independent t test, compared to control. 
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slightly higher tumor incidence (88% for EP1 deficient mice versus 66% for wild type 
mice) compared to wild type mice (Figure 3-2A and B). At the end of the experiments, 
the size of tumors was measured with calipers. EP1 deficient mice produced a similar 
ratio of medium-size tumors (58% for EP1 deficient mice versus 62% for wild type mice) 
but more small tumors (26% for EP1 deficient mice versus 16% for wild type mice) with 
fewer large tumors (17% for EP1 deficient mice versus 22% for wild type mice) (Figure 
3-2C). These data show that EP1 deficiency increases tumor development but decreases 
tumor size in the DMBA/TPA carcinogenesis protocol.  
 
3.3 EFFECT OF EP1 DEFICIENCY ON CELL PROLIFERATION   
In the absence of treatment, BrdU incorporation was similar in the epidermis of 
wild type and EP1 deficient mice. After one or four vehicle treatments, there was no 
change in BrdU incorporation in both wild type and EP1 deficient mice. Both one TPA 
(2.5 µg) and four treatments of TPA increased BrdU incorporation to the same extent in 
wild type and EP1 deficient mice (Figure 3-3). These data show that deficiency of EP1 
did not affect TPA-induced epidermal cell proliferation.  
 
3.4 EFFECT OF EP1 DEFICIENCY ON UV SKIN CARCINOGENESIS  
To examine the effect of EP1 deficiency on skin tumor development, a UV skin 
carcinogenesis protocol was used with EP1 deficient mice and wild type mice. For this 
experiment, EP1 deficient mice were backcrossed to the SKH strain background 5 times. 
While wild type mice produced the first tumor at 14 weeks of UV treatment, EP1 
deficient mice produced the first tumor at 13 weeks of UV treatment. Starting at week 23 
of UV treatment, wild type mice produced more tumors (average 2.7 for wild type mice 
 
Figure 3-2. The effect of EP1 deficiency in DMBA/TPA–induced skin tumor 
development. DMBA/TPA skin carcinogenesis protocol was used with 32 
EP1 deficient mice and 32 wild type mice. A, Tumor multiplicity; data are 
expressed as the average number of tumors per mouse. **p<0.01, Poisson 
regression. B, Tumor incidence; data are expressed as the percentage of 
mice bearing tumors. Open squares represent wild type mice. Closed 
triangles represent EP1 deficient mice. C, Tumor size ; Percentage of skin 
tumors by diameter size : Small < 2 mm ; Medium 2 – 5 mm; Large > 5 
mm. Open bars represent skin tumors from wild type mice. Closed bars 
represent skin tumors from knockout mice. * p<0.05, 2-sample test for 




Figure 3-3. DNA synthesis in the epidermis of EP1 deficient and wild type mice. Mice 
were topically treated with TPA (2.5 µg/200 µl) or acetone (200 µl). 
Seventeen hours after last treatment, mice were injected with BrdU. One 
hour later, dorsal skin was removed, fixed in formalin, and immunostained 




versus 1.8 for EP1 deficient mice) compared to wild type mice (Figure 3-4A). However, 
there was no difference statistically. Also, tumor incidence was very similar in wild type 
mice and EP1 deficient mice. (Figure 3-4B). These data show that EP1 deficiency does 
not affect skin tumor development in the UV carcinogenesis protocol.  
 
3.5 GENERATION OF BK5.EP1 CONSTRUCT 
Because PGE2 can inhibit the immune system, targeted overexpression of EP1 in 
the skin can serve as a useful model to study the role of EP1 in skin carcinogenesis. 
Therefore, BK5.EP1 transgenic mice which overexpress EP1 in the basal layer of the 
epidermis under the control of a bovine keratin 5 promoter were generated.  
To make BK5.EP1 transgenic mice, a BK5.EP1 construct had to be made first. 
Mouse EP1 cDNA (in pBluescript plasmid, pBluescript EP1) was a deeply appreciated 
gift from Dr. Sugimoto of Kyoto University, Japan (Figure 3-5). The strategy for making 
the BK5.EP1 construct is shown in Figure 3-6. The pBluesctipt EP1 plasmid was checked 
for fidelity by diagnostic restriction digests. EcoRI digestion produced the correct 
fragment sizes of 1312 bp and 2958 bp fragments. SmaI digestion produced the 
anticipated fragment sizes of 977 bp and 3293 bp. AlwNI digestion also produced the 
expected fragment sizes of 612 bp, 1065 bp and 2593 bp (Figure 3-7A). The EP1 cDNA 
was cut from pBluescript EP1 by digestion with EcoRI enzyme (Figure 3-7B). The pBK5 
vector (Figure 3-8) was also digested with SnaBI (Figure 3-7B). After the ligation 
reaction of EP1 cDNA into the pBK5 vector, E. coli were transformed and 13 colonies 
were picked and cultured. To determine that the plasmid had the correct orientation of 
EP1 in the pBK5 vector, a series of diagnostic restriction digestions were performed. By 
NheI and SmaI digestion, sense-ligated plasmid should produce 10.246 kb and 0.966 kb 
fragments but anti-sense-ligated plasmid should produce 10.866 kb and 0.347 kb 
 
Figure 3-4. The effect of EP1 deficiency in UV-induced skin tumor development. A UV 
skin carcinogenesis protocol was used with 25 EP1 deficient mice and 25 
wild type mice. A, Tumor multiplicity; Data are expressed as the average 
number of tumors per mouse. B, Tumor incidence; data are expressed as the 
percentage of mice bearing tumors. Open squares, wild type mice (WT); 




Figure 3-5. pBluescript EP1 plasmid. Mouse EP1 cDNA (1312 bp) was inserted into 
pBluescriptSK(-) (4270 bp). Coding region: 72-1289 bp. The pBLuescript 










Figure 3-7. Diagnostic digestion of EP1 and digestion of pBK5 and EP1 cDNA. A, 
diagnostic restriction digest of pBluescriptEP1. To check the fidelity of 
pBluesctiot EP1 plasmid, the pBluescriptEP1 plasmid was digested with 
EcoRI, SmaI and AlwNI. B, Digestion of pBK5 and EP1 cDNA. pBK5 





Figure 3-8. pBK5 plasmid. Keratin 5 promoter is followed by β-globin intron and SV 40 




fragments. With NheI and SfiI digestion, sense-ligated plasmid should produce 9.952 kb 
and 1.260 kb fragments but anti-sense ligated plasmid should produce 11.16 kb and 0.052 
kb fragments (Figure 3-9A). Plasmid #1, and #12 had the correct orientation (Figure 3-
10A). Colony #12 was cultured and checked by a series of diagnostic digestions – NheI 
and SmaI, NheI and SfiI, then KpnI and SmaI. KpnI and SmaI digestion should produce 
6.046 kb, 3 kb, and 2.166 kb fragments (Figure 3-10B). The BK5.EP1 DNA construct 
(Figure 3-9B) was cut by KpnI digestion (Figure 3-10C) and injected into fertilized eggs 
by the Science Park Transgenic Mouse Facility Core.  
 
3.6 GENERATION OF BK5.EP1 TRANSGENIC MICE 
Four BK5.EP1 transgenic founders (# 8, 9, 10 and 15) were identified by 
Southern blot analysis (Figure 3-11A). One founder (#10) did not produce any offspring. 
To examine the expression level of EP1 in epidermis, EP1 mRNA levels in epidermis 
from heterozygous offspring of each founder were measured by northern blot analysis. 
All three lines of BK5.EP1 transgenic mice showed significantly increased levels of EP1 
expression compared to wild type mice (Figure 3-11B). Line 8 and line 9 express about 
two-fold higher levels of EP1 mRNA compared to line 15. Therefore, line 8 heterozygous 
BK5.EP1 transgenic mice were used for all subsequent experiments.  
The BK5.EP1 transgenic mice had macroscopically normal skin and did not show 
any signs of health problems. When examined under a microscope, the epidermis of 
BK5.EP1 transgenic mice was slightly thicker than that of wild type mice. Other than 
that, there was no histological difference between wild type and BK5.EP1 transgenic 
mice (Figure 3-13). 
 
 
Figure 3-9. pBK5.EP1 plasmid and BK5.EP1 construct. A. pBK5.EP1 plasmid. Murine 








Figure 3-10. Characterization of the pBK5.EP1 plasmid. A. Diagnostic restriction 
digestion to determine correct orientation of EP1 in the pBK5 vector. 
Plasmid was digested with NheI and SfiI or Nhe and SmaI. B. Diagnostic 
restriction digestion of pBK5.EP1 to check fidelity. Plasmid was digested 
with NheI and SmaI, Nhe and SfiI and KpnI and SmaI. C. The BK5.EP1 
construct was cut from pBK5.EP1 by KpnI digestion for injection into 
fertilized eggs. 
 
Figure 3-11. Generation of BK5.EP1 transgenic mouse. A, Identification of founder 
BK5.EP1 transgenic mice. Genomic DNA was isolated from tails and used 
for Southern blot analysis. B, EP1 mRNA levels in epidermis from 
BK5.EP1 transgenic mice and wild type mice were analyzed by northern 
blot with specific EP1 probe.  
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3.7 EFFECT OF EP1 OVEREXPRESSION ON GENE EXPRESSION RELATED TO SIGNAL 
TRANSDUCTION PATHWAY 
To examine the effect of EP1 overexpression on gene expression, the mRNA 
expression level of 84 genes related to signal transduction in the epidermis of wild type 
and BK5.EP1 transgenic mice was analyzed by PCR array. The genes that are expressed 
more than 2-fold or less than 2-fold in BK5.EP1 transgenic mice compared to wild type 
mice are shown (Table 3-1). To confirm the increased level of tumor necrosis factor-α in 
the BK5.EP1 transgenic mice, the expression of TNF-α was measured by enzyme 
immunoassay. With vehicle treatment and TPA treatment, there was no difference in 
TNF-α levels in wild type mice and in BK5.EP1 transgenic mice (Table 3-2). Although 
the tumor necrosis factor-α mRNA level was increased in the untreated BK5.EP1 
transgenic mice, the tumor necrosis factor-α protein level was not increased in the 
untreated BK5.EP1 transgenic mice compared to the wild type mice. After TPA 
treatment, both the wild type and the BK5.EP1 transgenic mice induced similar levels of 
tumor necrosis factor-α protein.  
 
3.8 EFFECT OF EP1 OVEREXPRESSION ON DMBA/TPA SKIN CARCINOGENESIS 
To examine the effect of EP1 overexpression on skin tumor development, a 
DMBA/TPA skin carcinogenesis protocol was carried out with BK5.EP1 transgenic mice 
and wild type mice. In BK5.EP1 transgenic mice, the first tumor appeared 2 weeks after 
initiation, that is, prior to application of the promoter. By contrast, the first tumor 
appeared at 7 weeks after starting promotion in wild type mice. By week 7 of promotion, 
BK5.EP1 transgenic mice had more tumors and a greater tumor incidence than wild type 
mice. However, starting at 9 weeks of promotion, wild type mice produced more tumors 
 
Table 3-1. Representative genes that are expressed more than 2-fold or less than 2-fold in 
BK5.EP1 transgenic mice compared to wild type mice. Epidermal scrapes 
were collected from 3 mice for each group. Signal Transduction Pathway 




Table 3-2. Effect of EP1 expression on TNF- α level in skin epidermis. Level of TNF-α 
(pg/100 μg protein) was measured 2.5 hours after 200 μl of acetone (Ace) or 
2.5 μg/200 μl TPA treatment of wild type and BK5.EP1 transgenic mice by 




(average of 7.5 for wild type mice versus 3.1 for BK5.EP1 transgenic mice) with a higher 
tumor incidence (93%) compared to 81% for BK5.EP1 transgenic mice (Figure 3-12A 
and B). Interestingly, in BK5.EP1 transgenic mice the first carcinoma was observed at 5 
weeks of promotion but in the wild type mice the first carcinoma did not appear until 14 
weeks of promotion. By week 20 of promotion, BK5.EP1 transgenic mice produced 
many more carcinomas than wild type mice (26 for BK5.EP1 transgenic mice versus 3 
for wild type mice) (Figure 3-12C). At the end of the experiment, tumors larger than 2 
mm were collected and histologically examined. From BK5.EP1 transgenic mice, 24 
squamous cell carcinomas and 62 papillomas were collected. By contrast, wild type mice 
produced only 4 squamous cell carcinomas with 114 papillomas. Thus, BK5.EP1 
transgenic mice were found to have a higher papilloma to carcinoma conversion rate 
(28.0% v.s. 3.4%, p<0.001, Fisher’s exact test). The high rate of carcinoma production in 
BK5.EP1 transgenic mouse implies that EP1 is important in tumor progression.  
 
3.9 EFFECT OF EP1 OVEREXPRESSION ON TPA-INDUCED CELL PROLIFERATION 
In malignant keratinocytes, PGE2 and an EP1 agonist prevented NSAID-induced 
cell growth inhibition (Thompson, Gupta et al. 2001). Therefore, the effect of EP1 
overexpression in basal cells on cell proliferation was examined. Without any treatment, 
BrdU incorporation was similar in the epidermis of wild type and BK5.EP1 transgenic 
mice. In BK5.EP1 transgenic mice, BrdU incorporation was increased 2-fold compared to 
wild type mice treated once or four times with vehicle. However, one TPA (2.5 µg) or 
four treatments of TPA increased BrdU incorporation to the same extent in BK5.EP1 
transgenic mice and wild type mice (Figure 3-13A). Measurements of epidermal 
 
Figure 3-12. The effect of EP1 overexpression on DMBA/TPA–induced skin tumor 
development. A DMBA/TPA skin carcinogenesis protocol was used with 28 
BK5.EP1 transgenic mice and 28 wild type mice. A, Tumor multiplicity; 
data are expressed as the average number of tumors per mouse. B, Tumor 
incidence; data are expressed as the percentage of mice bearing tumors. C, 
Carcinoma multiplicity; data are expressed as the cumulative number of 
carcinomas. Open squares represent wild type mice. Closed diamonds 













Figure 3-13. Epidermal cell proliferation in BK5.EP1 transgenic and wild type mice. A, 
BrdU incorporation. Mice were topically treated with TPA (2.5 µg/200 µl) 
or acetone (200 µl). Seventeen hours after the last treatment, mice were 
injected with BrdU. One hour later, dorsal skin was removed, fixed in 
formalin, and immunostained for BrdU. The data are shown as percentage of 
BrdU positive basal cells. B, Epidermal thickness. Dorsal skin was collected 
18 hours after the last acetone (200 µl) or TPA (2.5 µg/200 µl acetone) 
treatment and stained with H&E. Epidermal thickness was measured under 
the microscope. 1X Ace, one acetone (200 µl) treatment; 1X TPA, one TPA 
(2.5 µg/200 µl acetone) treatment; 4X Ace, acetone (200 µl) treatment every 
three days for 4 treatments, 4X TPA, TPA (2.5 µg/200 µl acetone) treatment 
every three days for 4 treatments. 
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thickness revealed that the epidermis was slightly thicker in BK5.EP1 transgenic mice 
without any treatment or after one vehicle treatment. Eighteen hours after one TPA 
treatment, the epidermis of BK5.EP1 transgenic mice was still slightly thicker than that 
of wild type mice. However, 18 hours after four applications of vehicle or TPA, the 
epidermal thickness of wild type and BK5.EP1 transgenic mice was very similar (Figure 
3-13B). These data showed that overexpression of EP1 does not affect TPA-induced 
proliferation. Because deficiency of EP1 also did not affect TPA induced epidermal cell 
proliferation, it is concluded that the level of EP1 expression does not affect TPA induced 
epidermal cell proliferation.  
 
3.10 EFFECT OF EP1 EXPRESSION LEVEL ON TPA-INDUCED SIGNALING  
It has been shown that an EP1 agonist induces COX-2 in mouse osteoblastic cells 
(Suda, Tanaka et al. 2000). Therefore, the effect of EP1 overexpression on TPA-induced 
COX-2 expression was examined by western blot. Without any treatment, there was no 
COX-2 protein expression in the skin epidermis of wild type mice. However, in wild type 
mice COX-2 expression was induced 3 hours after 2.5 μg of TPA treatment, with a 
maximum induction occurring at 6 hours after TPA treatment. In the BK5.EP1 transgenic 
mice, however, COX-2 was expressed in the absence of TPA. Interestingly, the COX-2 
expression level was not changed by TPA treatment in the BK5.EP1 transgenic mice. 
That is, at 6 hours after TPA treatment wild type mice expressed more COX-2 than the 
BK5.EP1 transgenic mice (Figure 3-14A). The effect of EP1 deficiency on TPA-induced 
COX-2 was determined by western blot. At 3 hours after TPA treatment, both wild type 
and EP1 deficient mice had a moderate level of COX-2 induction. At 6 hours after TPA 
treatment, in EP1 deficient mice COX-2 induction was similar to that of wild type mice 
(Figure 3-14B). That is, overexpression of EP1 induced COX-2 without TPA application 
 
 
Figure 3-14. Effect of EP1 overexpression on TPA-induced signaling. A. Protein was 
extracted from epidermis at specified times after acetone (Ace) or TPA 
treatment of wild type (WT) and BK5.EP1 transgenic mice (EP1 TG). COX-
2 protein level was determined by western blot. Actin protein levels were 
used as loading controls. B. Protein was extracted from epidermis at 
specified times after acetone (Ace) or TPA treatment of wild type (WT) and 
EP1 deficient mice (EP1 KO). COX-2 protein level was determined by 
western blot. Actin protein levels were used as loading controls. C. Protein 
was extracted from epidermis at specified times after acetone (Ace) or TPA 
treatment of wild type (W) and BK5.EP1 transgenic mice (T). pEGFR 
(Y1086) protein level was determined by western blot. The same blot was 
striped and probed with an antibody that recognizes EGFR. D. Protein was 
extracted from epidermis of untreated wild type (WT) and BK5.EP1 
transgenic mice (EP1 TG). pStat 3 protein level was determined by western 
blot. The same blot was striped and probed with an antibody that recognizes 




but TPA did not further induce COX-2. These data could be a clue for determining the 
underlying mechanism of why BK5.EP1 transgenic mice produced fewer tumors than 
wild type mice in response to TPA. 
It has been shown that EP1 transactivates EGFR in human cholangiocarcinoma 
cells (Han and Wu 2005). Therefore, the effect of EP1 overexpression on TPA-induced 
EGFR phosphorylation was also examined by western blot. TPA induced maximum 
phosphorylation of EGFR at 2 hours after TPA treatment in wild type mice. In BK5.EP1 
transgenic mice, TPA also induced phosphorylation of EGFR at 2 hours but to a much 
lower extent than observed in wild type mice. At 3 hours after TPA treatment, the level of 
pEGFR was slightly reduced but still higher than vehicle-treated wild type mice. 
However, at 3 hours after TPA treatment, the level of pEGFR was completely back to 
normal level in BK5.EP1 transgenic mice (Figure 3-14C). Interestingly, overexpression 
of EP1 induced less pEGFR after TPA treatment and that is possibly one of the reasons 
why the BK5.EP1 transgenic mice produced fewer tumors than wild type mice in the 
DMBA/TPA induced skin carcinogenesis protocol. 
An EP1 antagonist pretreatment effectively blocked PGE2 induced Stat3 
phosphorylation in human cholangiocarcinoma cells (Han, Demetris et al. 2006). 
Therefore, the effect of EP1 overexpression on TPA-induced Stat3 phosphorylation was 
also examined by western blot. With vehicle treatment, there was no phosphorylated 
Stat3 detectable in either the BK5.EP1 transgenic or the wild type mice. Both wild type 
and BK5.EP1 transgenic mice induced a similar level of phosphorylated Stat3 at 3 hours 
after TPA treatment. By 6 hours after TPA treatment, the phosphorylated Stat3 level was 
reduced but still higher than normal level in both the wild type and the BK5.EP1 
transgenic mice. There was no change in total Stat3 expression (Figure 3-14D). 
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Phosphorylated Stat3 level was not affected at all by overexpression of EP1. That is, the 
Stat3 pathway seems not important in EP1-mediated signaling. 
 
3.11 EFFECT OF EP1 OVEREXPRESSION ON DMBA/ANTHRALIN SKIN 
CARCINOGENESIS  
Since one of the downstream signaling molecules of the EP1 receptor is PKC 
(Krysan, Reckamp et al. 2005), the expression level of PKC in the BK5.EP1 transgenic 
mice was examined. PKC protein expression level decreased in the BK5.EP1 transgenic 
mice compared to wild type mice (Figure 3-15A). Therefore, another tumor promoter, 
anthralin, which generates free radicals and does not interact with PKC was used 
(Battalora, Johnston et al. 1995; Bol, Rowley et al. 2002). The first tumor that developed 
in BK5.EP1 transgenic mice was observed at 2 weeks after initiation whereas in wild 
type mice the first tumor formed at 29 weeks after promotion. From week 33 of 
promotion, tumor multiplicity and tumor incidence were increased 2-fold in BK5.EP1 
transgenic mice but there was no difference statistically (Figure 3-15B, C). By week 57 
of promotion, BK5.EP1 transgenic mice produced 9 carcinomas while wild type mice 
produced only one carcinoma. In this experiment, anthralin produced fewer papillomas 
compared TPA. While the BK5.EP1 transgenic mice produced fewer tumors with TPA 
tumor promotion, the BK5.EP1 transgenic mice produced slightly more tumors with 
anthralin tumor promotion. Notably, the BK5.EP1 transgenic mice produced more 
carcinomas than wild type mice in both TPA tumor promotion and anthralin tumor 
promotion. These data imply that EP1 signaling pathway is more important in 




Figure 3-15. The effect of EP1 overexpression on DMBA/anthralin–induced skin tumor 
development. A. Protein was extracted from epidermis of untreated wild 
type (WT) and BK5.EP1 transgenic mice (EP1 TG). PKC protein level was 
determined by western blot. Actin protein levels were used as loading 
controls. B-C, DMBA/anthralin skin carcinogenesis protocol was used with 
32 BK5.EP1 transgenic mice and 32 wild type mice. B, Tumor multiplicity; 
data are expressed as the average number of tumors per mouse. C, Tumor 
incidence; data are expressed as the percentage of mice bearing tumors. 
Open squares represent wild type mice. Closed diamonds represent 




3.12 EFFECT OF EP1 OVEREXPRESSION ON UV SKIN CARCINOGENESIS MODEL 
A UV carcinogenesis model was employed in that it is more relevant to humans 
than other carcinogenesis models used. The first tumor developed at 4 weeks of UV 
exposure in BK5.EP1 transgenic mice, whereas the first tumor was observed at 21 weeks 
of UV exposure in wild type mice. At 41 weeks, BK5.EP1 transgenic mice had an 
average of 1 tumor /mouse, whereas wild type mice produced an average of 0.58 
tumors/mouse (Figure 3-16A). However, there was no difference between wild type and 
the BK5.EP1 transgenic mice statistically. The first carcinoma appeared at 29 weeks after 
UV treatment in both groups. While BK5.EP1 transgenic mice produced 14 carcinomas 
by week 50, wild type mice produced 8 carcinomas (Figure 3-16B). Thus, while 
overexpression of EP1 produces only slightly more tumors than wild type mice in the UV 
induced carcinogenesis protocol, the BK5.EP1 transgenic mice produced significantly 
more carcinomas than wild type mice.  
 
3.13 EFFECTS OF EP1 OVEREXPRESSION ON DMBA-ONLY SKIN CARCINOGENESIS  
Since tumor formation was observed in EP1 transgenic mice prior to application 
of the tumor promoter TPA, a DMBA-only experimental protocol was used. However, 
the dose of DMBA (400 μg) was higher than in the DMBA/TPA protocol (100 μg) to 
ensure tumor formation in wild type mice. More tumors and a 100% incidence were 
observed at 3 weeks after DMBA treatment in BK5.EP1 transgenic mice (average 7 
tumors/mouse) than wild type mice (average 1 tumor/mouse) (Figure 3-17A and B). 
There are two reasons for the declining tumor multiplicity seen after week 4. Tumors 
formed fairly close together and coalesced. Mice with larger than 10 mm carcinoma were 
sacrificed in the middle of the experiment for humane reasons. The first carcinoma  
 
Figure 3-16. The effect of EP1 overexpression in UV-induced skin tumor development. A 
UV skin carcinogenesis protocol was used with 26 BK5.EP1 transgenic 
mice and 26 wild type mice. A, Tumor multiplicity; data are expressed as 
the average number of tumors per mouse. B, Cumulative number of 
carcinoma; data are expressed as cumulative number of carcinomas. Open 








Figure 3-17. The effect of EP1 overexpression in DMBA-only skin tumor development. 
A DMBA-only skin carcinogenesis protocol was used with 32 BK5.EP1 
transgenic mice and 32 wild type mice. A, Tumor multiplicity; data are 
expressed as the average number of tumors per mouse. * p<0.001, Poisson 
regression. B, Tumor incidence; data are expressed as the percentage of 
mice bearing tumors. * p<0.001, Fisher exact test. C, Cumulative number of 
carcinomas; data are expressed as cumulative number of carcinomas. Open 
squares, wild type mice (WT); Closed diamonds, BK5.EP1 transgenic mice 
(EP1 Tg). D, Two weeks after DMBA treatment; E, Four weeks after 




formed at 4 weeks after DMBA treatment in BK5.EP1 transgenic mice, whereas no 
carcinoma formation was observed in wild type mice by week 49 after DMBA treatment 
(Figure 3-17C). The photograph taken from another set of mice 2 weeks after application 
of DMBA (400 μg), clearly shows that the BK5.EP1 transgenic mice develop lesions 
while the wild type mice have macroscopically normal skin (Figure 3-17D). Four weeks 
after DMBA treatment, the BK5.EP1 transgenic mouse had some papillomas but the wild 
type mice had no tumors (Figure 3-17E). At 6 weeks after DMBA treatment, the 
BK5.EP1 transgenic mouse had 4 papillomas and a carcinoma whereas the wild type 
mice developed no tumors (Figure 3-17F). These data clearly show that overexpression 
of EP1 enhanced malignant tumor formation in the DMBA-only skin carcinogenesis 
protocol. Thus, overexpression of EP1 alone has tumor promoting activity and enhances 
progression.  
 
3.14 EFFECT OF EP1 OVEREXPRESSION ON TUMOR INITIATION 
The effect of EP1 overexpression on skin tumor initiation was examined by 
measuring B[a]P-DNA adduct formation to find the underlying mechanism of how EP1 
overexpression increased DMBA-induced tumor development. 3H-DMBA was not 
practically available. B[a]P and DMBA are polycyclic aromatic hydrocarbons and are 
metabolized by the CYP1 enzyme to reactive forms (DiGiovanni 1992). Therefore, 3H-
B[a]P was used. Fifteen hours after 200 nmol, 200 μCi of 3H-B[a]P treatment, wild type 
mice had an average of 7.4 pmol adduct/mg DNA while EP1 transgenic mice produced 
6.5 pmol adduct/mg DNA. The effect of EP1 overexpression on CYP1B1, the enzyme 
that metabolizes DMBA to reactive intermediates, expression was also examined by 
western blot. After vehicle treatment or TPA treatment, there was no change in the 
CYP1B1 expression level (Figure 3-18A). Activation of EP1 possibly activates Ras 
 
 
Figure 3-18. Effect of EP1 overexpression on initiation. A. Protein was extracted from 
epidermis at specified times after acetone (Ace) or TPA treatment of wild 
type (WT) and BK5.EP1 transgenic mice (TG). CYP1B1 protein level was 
determined by western blot. Actin protein levels were used as loading 
controls. B. Protein was extracted from epidermis of untreated wild type 
(WT) and BK5.EP1 transgenic mice (TG). Ras-GTP protein level was 
determined by pull down assay. PC, positive control, untreated wild type 
protein treated with GTPγS before pull down; NC, negative control, 
untreated wild type protein treated with GDP before pull down. Total Ras 




through activation of PLC (Dhanasekaran, Tsim et al. 1998). Therefore, the level of Ras 
activity was measured by a pull-down assay. Untreated BK5.EP1 transgenic mice had a 
similar level of epidermal ras activity as wild type mice (Figure 3-18B). These data show 
that overexpression of EP1 does not affect tumor initiation.  
 
3.15 EFFECT OF EP1 OVEREXPRESSION ON DMBA– INDUCED CELL PROLIFERATION 
Because overexpression of EP1 did not affect tumor initiation, the effect of EP1 
overexpression on DMBA-induced epidermal cell proliferation was examined by 
assessing Ki-67 incorporation and epidermal thickness. With vehicle (acetone, 200 µl) 
treatment, Ki-67 incorporation and epidermal thickness was similar in wild type and 
BK5.EP1 transgenic mice (Figure 3-19). Five days after 400 µg of DMBA treatment, 
BK5.EP1 transgenic mice showed an increase in Ki-67 incorporation that was about 
twice that of the wild type mice (75.6% for BK5.EP1 transgenic mice versus 36.8% for 
wild type mice) (Figure 3-19A). Two days after DMBA treatment, epidermal thickness in 
BK5.EP1 transgenic mice showed an increase twice that of wild type mice (66.6 µm for 
BK5.EP1 transgenic mice versus 35.7 µm for wild type mice). Five days after DMBA 
treatment, the epidermis of BK5.EP1 transgenic mice was still thicker than that of the 
wild type mice (73.5 µm for BK5.EP1 transgenic mice versus 55.4 µm for wild type 
mice) (Figure 3-19B). These data clearly show that overexpression of EP1 increases 
DMBA-induced epidermal cell proliferation.  
 
3.16 THE EFFECT OF EP1 OVEREXPRESSION ON SKIN CARCINOGENESIS IS COX-2 
DEPENDENT 
Previous research reported that the EP1 agonist 17-phenyl-2-trinor PGE2 induces 








Figure 3-19. Effect of DMBA on epidermal cell proliferation and hyperplasia in 
BK5.EP1 transgenic and wild type mice. A, Ki-67 incorporation. Mice were 
topically treated with DMBA (400 µg/200 µl) or acetone (200 µl). At 
specified times after treatment, dorsal skin was removed, fixed in formalin, 
and immunostained for Ki-67. The data are shown as percentage of Ki-67 
positive basal cells. B, Epidermal thickness. Dorsal skin was collected at 
specified times after acetone (200 µl) or DMBA (400 µg/200 µl acetone) 
treatment and stained with H&E. Epidermal thickness was measured under a 
microscope. Ace, acetone (200 µl) treatment; DMBA, DMBA (400 µg/200 
µl acetone) treatment. * p <0.05, independent T test, compared to WT, ** 
p<0.01, independent T test, compared to WT, *** p <0.001, independent 
proportions test, compared to WT.  
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(Suda, Tanaka et al. 1998). In addition, application of the EP1 antagonist ONO-8713 on 
mouse skin effectively prevents UV-mediated induction of PGE2 (Tober, Wilgus et al. 
2006). As previously reported (Athar, An et al. 2001; Bol, Rowley et al. 2002), there was 
no COX-2 protein expression in wild type mouse epidermis, whereas the COX-2 protein 
was clearly induced without any treatment in BK5.EP1 transgenic mice (Figure 3-20A). 
To determine the significance of upregulated COX-2 in BK5.EP1 transgenic mouse, 
Celecoxib (1000 ppm in the diet) was administered starting 1 week before DMBA 
treatment. The BK5.EP1 transgenic mice that were fed AIN control diet produced an 
average of four skin lesions at 2 weeks after DMBA treatment. As expected, the 
BK5.EP1 transgenic mice that were fed Celecoxib did not produce any lesions or tumors 
after DMBA treatment (Figure 3-20B). Two weeks after DMBA treatment, hyperplasia 
of the epidermis and more inflammatory cell infiltration in the dermis were observed in 
BK5.EP1 transgenic mice fed control diet. However, celecoxib fed BK5.EP1 transgenic 
mice showed a fairly normal skin architecture (Figure 3-20C and D). Induction of COX-2 
increases PGE2 levels, the ligand that binds the EP1 receptor. Therefore, EP1 signaling 
will be enhanced. These data show that expression of COX-2 in the BK5.EP1 transgenic 
mice is very important in the increased tumor development of these mice in the DMBA-




Figure 3-20. The effect of EP1 overexpression on DMBA-induced skin carcinogenesis is 
COX-2 dependent. A. Protein was extracted from epidermis of untreated 
wild type (WT) and BK5.EP1 transgenic mice (TG). COX-2 protein level 
was determined by western blot. Actin protein levels were used as loading 
controls. B. Groups of six mice were fed AIN-control diet or AIN diet 
containing Celecoxib (1000 ppm) starting one week before a single DMBA 
(400 µg) application. C-D. Two weeks after DMBA treatment, a skin 
sample of one mouse from each group was collected, fixed in formalin and 
stained with H&E. C. Skin of AIN-control diet fed mice. D. Skin of 




Chapter 4 Discussion  
EP1 is expressed in normal human epidermis as well as in normal mouse 
epidermis (Lee, Kim et al. 2005). Increased EP1 mRNA levels in tumor promoter (TPA 
and UV) treated epidermis and DMBA/TPA or UV-induced tumors in this study imply 
increased EP1 signaling after application of tumor promoter and in tumors. These data 
are in agreement with Lee’s publication (Lee, Kim et al. 2005) which showed that EP1 
mRNA level was increased in UV treated mouse skin, UV-induced papilloma and 
squamous cell carcinoma (SCC) in mouse and human (Lee, Kim et al. 2005) and in 2-
amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced mammary tumors (Kawamori, 
Uchiya et al. 2001). According to Lee’s publication (Lee, Kim et al. 2005), all UV-
induced mouse papillomas and SCC expressed EP1 and more than 90% of human actinic 
keratosis samples as well as 75% of human SCC expressed EP1. Since EP1 is 
upregulated in tumor promoter treated skin and tumors, overexpression of EP1 in the skin 
could be a useful system to study the role of EP1 in skin carcinogenesis in vivo. 
Therefore, transgenic mice which overexpress EP1 in the basal layer of the skin were 
made. 
The BK5.EP1 transgenic mice did not develop any health problems. Body size of 
the BK5.EP1 transgenic mice was similar to that of wild type mice. There were no 
reproductive problems in breeding of the BK5.EP1 transgenic mice. Also, the BK5.EP1 
mice had macroscopically normal hair coat and skin.  
In untreated BK5.EP1 transgenic mice, no changes in cell proliferation (BrdU 
incorporation and epidermal thickness) were observed as compared to wild type mice. 
However, a slight increase in inflammatory cells in the dermis of the BK5.EP1 transgenic 
mice led us to assess the level of pro-inflammatory gene expression. As expected, 
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microarray data show that there are some changes in gene expression in untreated 
BK5.EP1 transgenic mice skin compared to wild type skin. Anti-apoptotic protein NAIP 
(neuronal apoptosis inhibitory protein) is increased in the BK5.EP1 transgenic mice. 
NAIP does not inhibit caspases directly (Roy, Deveraux et al. 1997) but inhibits 
apoptosis (Gotz, Karch et al. 2000). Thus, overexpression of EP1 might affect apoptosis 
through induction of NAIP. Overexpression of EP1 also increased Wnt expression. After 
Wnt ligand binds the Frizzled receptor, GSK-3β is inactivated and β-catenin is released. 
Then the free β-catenin moves into the nucleus and associates with Tcf and Lef, which  
induces target gene expression such as c-myc, c-jun, cyclin D1, VEGF and COX-2 
(Bhatia and Spiegelman 2005; Telliez, Furman et al. 2006; Eisinger, Prescott et al. 2007). 
COX-2 induction in BK5.EP1 transgenic mice might be through this induction of Wnt.  
There was extensive induction of aromatase in BK5.EP1 transgenic mice. 
Aromatase is an enzyme that converts androgen into estrogen and is expressed in 
reproductive systems such as placenta, ovary, as well as in other tissues such as adipose 
tissue, liver, intestine, brain and skin fibroblasts (Simpson, Mahendroo et al. 1994). In 
accordance with our data, human keratinocytes also express aromatase (Hughes, 
Robinson et al. 1997). There are several reports in the literature that show EP1 affects 
aromatase expression. In human adenocortical carcinoma cell line, EP1 antagonist 
inhibited EGF-induced aromatase upregulation (Watanabe, Noda et al. 2006). In human 
adipose stromal cells, the EP1 agonist 17-phenyl trinor PGE2 increased aromatase 
expression and activity (Richards and Brueggemeier 2003). In primary human breast 
stromal cells, the EP1 agonist 17-phenyl trinor PGE2 increased aromatase activity and an 
EP1 antagonist prevented induction of aromatase activity by PGE2 (Brueggemeier, 
Richards et al. 2001). The role of estrogen in the skin has been shown in several literature 
reports. 17β-Estradiol administration increased epidermal thickness (Azzi, El-Alfy et al. 
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2005). 17β-Estradiol increased cell proliferation through cyclin D2 as well as increasing 
GM-CSF secretion in normal human keratinocytes (Kanda and Watanabe 2004). Also, 
both estrogen receptor (ER) alpha and beta are expressed in human keratinocytes 
(Ohnemus, Uenalan et al. 2006).  
Matrix metalloproteinases (MMPs) are proteolytic enzymes and activate typsin- 
or plasmin-activated procollagenase-I and other MMPs by cleavage of the prodomain. 
MMPs are important in tumor progression for enhancing angiogenesis and breaking 
down extracellular matrix and basement membrane. Thus MMPs enhance tumor growth 
and metastasis (Kerkela, Ala-aho et al. 2001). In the skin, MMP-10 (Stromelysin-2) is 
induced by wounding, TNF-alpha, TGF-alpha, and EGF treatment (Windsor, Grenett et 
al. 1993; Madlener, Mauch et al. 1996). Enhanced tumor progression in the BK5.EP1 
transgenic mice could be partly due to increased MMP-10 expression.  
In the BK5.EP1 transgenic mice, there was an increase of several 
proinflammatory factors such as CCL1, CXCL20, CSF2, and COX-2. Inflammation is a 
tissue change in response to injury. Characteristics of inflammation are vasodilation, 
edema, clotting, migration of innate immune cells and swelling of tissue cells (Guyton 
1996). Chronic inflammation increases risk of cancer development in bladder, stomach, 
liver, colon and ovary (Moore, Owens et al. 1999). Cancers are rich in inflammatory 
cytokines, chemokines, and inflammatory enzymes. These inflammatory cytokines can 
affect tumor growth, invasion and angiogenesis directly and/or indirectly (Mantovani 
2005). 
ICAM-1 is a transmembrane glycoprotein and binds to integrins, fibrinogen and 
extracellular matrix factor hyaluronan that mediates cell-cell adhesion. In ICAM-1 
deficient mice, leukocyte migration to inflammatory sites is decreased, reducing the 
inflammatory reaction (van de Stolpe and van der Saag 1996). UVA induces ICAM-1 
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mRNA and protein in normal keratinocytes (Krutmann 2000). Increased ICAM-1 
expression in keratinocytes is observed in inflammatory dermatoses and allergic skin 
reactions (van de Stolpe and van der Saag 1996). Chemokine ligand 1 (CXCL1) is 
expressed in normal human epidermis and induced during wound healing and psoriatic 
skin (Payne and Cornelius 2002; Zaja-Milatovic and Richmond 2008). CXCL1 recruits 
neutrophils. PKC-alpha transgenic mice induced more CXCL1 after TPA treatment 
compared to wild type mice in a NF-κB-dependent manner (Cataisson, Pearson et al. 
2006). In human colorectal cancer cells, PGE2 induces CXCL1 (Wang, Wang et al. 
2006).  CCL20 (macrophage inflammatory protein-3α) attracts dendritic cell and 
Langerhans cell precursors (Zhou, Krueger et al. 2003). In human primary keratinocytes, 
IL-1beta, TNF-alpha, and S100A8/A9 treatment induced CCL20 (Dieu-Nosjean, 
Massacrier et al. 2000) (Nukui, Ehama et al. 2008). In GM-CSF deficient mice, wound 
healing was delayed (Fang, Gong et al. 2007). UVA treatment induced GM-CSF in 
cultured human keratinocytes (Imokawa, Yada et al. 1996). Epidermal keratinocytes 
produce GM-CSF under normal conditions and GM-CSF is induced in response to TPA, 
lipopolysaccharides, and UV (Gallo, Grabbe et al. 1992). In lung carcinoma cell lines, a 
COX-2 inhibitor suppressed GM-CSF production suggesting that PGE2 is involved in 
GM-CSF induction (Nakata, Uemura et al. 2003). In mast cells, PGE2 enhanced GM-CSF 
level (Gomi, Zhu et al. 2000). The upregulation of inflammatory mediators suggests that 
EP1-induced inflammation likely contributes to enhanced tumor progression, These 
changes needed to validated at the protein level and their functional significance 
determined.  
While untreated wild type mice do not express COX-2 in the epidermis, in the 
untreated BK5.EP1 transgenic epidermis, COX-2 protein levels are elevated. In 
agreement with our data, an EP1 agonist was reported to induce COX-2 in mouse 
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osteoblastic cells (Suda, Tanaka et al. 1998). Thus, elevated levels of prostaglandin are 
expected in the BK5.EP1 transgenic mice. Along with overexpression of EP1 in the 
BK5.EP1 transgenic mice, EP1 signaling will be more potentiated due to high level of the 
agonist, PGE2. Thus, a possible EP1  COX-2  PGE2  EP1 positive feedback loop 
may exist. Due to increased levels of proinflammatory factors, inflammation and a 
proliferative epidermis would be expected in the BK5.EP1 transgenic mice. Compared to 
wild type mice, BK5.EP1 transgenic mice have a mild increase in inflammatory cells in 
the dermis without any treatment, with TPA treatment and after DMBA treatment. 
Therefore, more detailed research on the effect of EP1 on recruitment of inflammatory 
cells needs to be carried out in the future.  
There are several reports in the literature that show the importance of EP1 in cell 
proliferation (Kimura, Osumi et al. 2001; Thompson, Gupta et al. 2001; Kawamori, 
Kitamura et al. 2005; Niho, Mutoh et al. 2005). In this study, both the BK5.EP1 
transgenic mice and EP1 deficient mice produced similar levels of epidermal 
proliferation after TPA treatment. Thus, EP1 expression level did not affect TPA induced 
epidermal proliferation. 
In response to TPA, wild type mice induced COX-2 protein maximally at 6 hours. 
However, in the BK5.EP1 transgenic mice, COX-2 expression levels were not affected 
by TPA treatment. Thus, at 6 hours after TPA treatment, wild type mice expressed more 
COX-2 than the BK5.EP1 transgenic mice. Therefore, it would be expected that wild type 
mice produce more prostaglandin than the BK5.EP1 transgenic mice after TPA treatment. 
Because COX-2 induction is an important feature in DMBA/TPA skin carcinogenesis 
model (Muller-Decker, Kopp-Schneider et al. 1998; Tiano, Loftin et al. 2002), this could 
explain why the BK5.EP1 transgenic mice produced fewer tumors in the DMBA/TPA 
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skin carcinogenesis model. However, EP1 deficient mice induced similar levels of COX-
2 at 6 hours after TPA treatment.  
Interestingly, in the DMBA/TPA skin carcinogenesis model, the BK5.EP1 
transgenic mice produced fewer tumors than wild type mice while the EP1 deficient mice 
produced more tumors than wild type mice. Thus, EP1 level inversely correlated with 
tumor formation in the DMBA/TPA skin carcinogenesis model. Similarly, skin cancer 
development was substantially reduced in transgenic mice overexpressing COX-2 and in 
transgenic mice overexpressing PKCε compared to wild type mice in the DMBA/TPA 
skin carcinogenesis model (Reddig, Dreckschmidt et al. 2000; Bol, Rowley et al. 2002; 
Muller-Decker, Neufang et al. 2002; Rundhaug, Mikulec et al. 2007). This effect was 
dependent on the type of tumor promoter used. When anthralin, UV, or no promoters 
were used, BK5.EP1 transgenic mice produced similar or a greater number of tumors 
than wild type mice. This suggests that there is an interaction between EP1 signaling and 
TPA signaling. PKC down-regulation in the BK5.EP1 transgenic mice can be one 
possible reason why TPA promotion does not produce more tumors in the BK5.EP1 
transgenic mice than in wild type mice while other promoters (UV, anthralin, or no 
promoter) produced more tumors in the BK5.EP1 transgenic mice than in wild type mice. 
Although the total tumor numbers were reduced in BK5.EP1 transgenic mice, many more 
carcinomas were produced, starting much earlier and with a greater papilloma to 
carcinoma conversion rate compared to wild type. This is similar to what was reported in 
PKCε transgenic mice (Jansen, Verwiebe et al. 2001).  
EGFR is subclassⅠof the receptor tyrosine kinase family, which has four 
members: EGFR (ErbB1) HER2/neu (ErbB2) HER3 (ErbB3) HER4 (ErbB4); skin 
expresses ErbB1, ErbB2 and ErbB3 (Stoll, Kansra et al. 2001). EGF is induced in the 
TPA treated skin and after TPA treatment, in tumors, expression levels of EGFR as well 
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as EGFR ligands are high (Woodburn 1999; Bol, Rowley et al. 2002; Hynes and Lane 
2005; Maubec, Duvillard et al. 2005). Overexpression of TGF-α, an EGFR ligand, in the 
epidermis induced hyperplasia and spontaneous papilloma formation (Wang, Greenhalgh 
et al. 1994). V-ras transduced, EGFR-deficient keratinocytes, as compared to wild type 
keratinocytes, produced a reduced tumor volume when injected onto nude mice (Dlugosz, 
Hansen et al. 1997). Activation of EP1 has been shown to induce transactivation of 
EGFR in hepatocytes, lung cancer cells and cholangiocarcinoma cells (Kimura, Osumi et 
al. 2001; Su, Shih et al. 2004; Han and Wu 2005). The BK5.EP1 transgenic mice also had 
a higher level of phosphorylation of EGFR than did wild type mice. However, this 
response is weak and transient in the BK5.EP1 transgenic mice. 
Signal transducers and activators of transcription (STATs) are transcription 
factors. An EGFR inhibitor reduced TPA-induced Stat3 activation (Chan, Carbajal et al. 
2004). In the skin, Stat3 is important in both the initiation and promotion stage of skin 
carcinogenesis (Kataoka, Kim et al. 2008). Due to transient phosphorylation of EGFR 
after TPA treatment in the BK5.EP1 transgenic mice, it might be expected that BK5.EP1 
transgenic mice have reduced activation of Stat3 in response to TPA. However, both wild 
type and BK5.EP1 transgenic mice induced a similar level of phospho-Stat3 after TPA 
treatment. 
The importance of EP1 in UV-induced skin carcinogenesis has been suggested by 
several studies. EP1 expression was increased in human SCC as well as UV-induced 
papilloma and SCC in mouse skin (Lee, Kim et al. 2005). In this study, increased 
expression of EP1 was also observed in UV-exposed skin and UV-induced tumors. Also, 
topical treatment with an EP1 antagonist reduced UV-induced skin carcinogenesis 
(Tober, Wilgus et al. 2006). In agreement with these studies, BK5.EP1 transgenic mice 
produced more tumors and EP1 deficient mice produced fewer tumors in the UV- 
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induced skin carcinogenesis model. Thus, EP1 contributes to UV-induced skin 
carcinogenesis. 
Papilloma formation before TPA application led us to suspect that EP1 has the 
ability to endogenously promote tumors. Therefore, a DMBA-only skin carcinogenesis 
protocol was used to test the tumor promoting action of EP1 signaling. BK5.EP1 
transgenic mice increased tumor development compared to wild type in the DMBA-only 
carcinogenesis protocol. Again, this observation is similar to PKCε transgenic mice and 
COX-2 transgenic mice, since PKCε transgenic mice show increased carcinoma 
development in a DMBA/acetone protocol and COX-2 transgenic mice produce more 
tumors with a DMBA-only protocol (Reddig, Dreckschmidt et al. 2000; Jansen, 
Verwiebe et al. 2001; Rundhaug, Pavone et al. 2007).  
To determine the mechanism by which EP1 overexpression increases tumor 
formation in DMBA-only skin carcinogenesis model, B[a]P-DNA adduct formation, 
CYP1B1 level and Ras activation levels were determined. The level of expression of 
CYP1B1, a cytochrome P450 enzyme that metabolizes DMBA to its active carcinogenic 
form, did not change in the BK5.EP1 transgenic mice compared to wild type mice. 
B[a]P-DNA adduct formation was also similar in the BK5.EP1 transgenic mice compared 
to wild type mice. In addition, the amount of the active form of Ras protein level was also 
not changed in the BK5.EP1 transgenic mice compared to wild type mice. Thus, EP1 
overexpression did not affect these aspects of the initiation stage of skin carcinogenesis.  
However, BK5.EP1 transgenic mice showed a greater proliferative response and 
inflammatory cell recruitment after DMBA treatment. These features likely contribute to 
the tumor promoting activity of EP1. 
Administration of Celecoxib, a COX-2 selective inhibitor, completely blocked 
DMBA-induced tumor formation in the BK5.EP1 transgenic mice. Thus, COX-2 
 87
overexpression is a very important downstream event in EP1 signaling in the DMBA –
induced skin carcinogenesis model. In the mouse mammary epithelial cell line, COX-2 
expression level was inversely correlated with smad3 expression (Neil, Johnson et al. 
2008). In DMBA/TPA induced skin SCC, smad3 expression level was reported to be 
significantly reduced (He, Cao et al. 2001). When v-ras transduced smad3 deficent 
keratinocytes were injected onto nude mice, papilloma formation was reduced but 
carcinoma formation was greatly enhanced compared to wild type keratinocytes 
(Vijayachandra, Lee et al. 2003). Therefore, it is possible that increased expression of 
COX-2 in the BK5.EP1 transgenic mice affects smad signaling and thus affects tumor 
progression.  
In all four skin carcinogenesis models used, BK5.EP1 transgenic mice produced 
more carcinomas than wild type mice. These data strongly suggest that EP1 is important 
in the progression stage of tumor development. One of characteristics of the tumor 
progression stage is invasion. Therefore, to understand how EP1 overexpression affects 
tumor progression, the role of EP1 overexpression in invasion needs to be studied in the 
future. 
In summary, EP1 expression was increased in tumor promoter treated mouse skin 
and mouse skin tumors. BK5.EP1 transgenic mice produced more SCC than did wild 
type mice. BK5.EP1 transgenic mice had a similar proliferative response after TPA 
treatment but a greater poliferative response after DMBA treatment than did wild type 
mice. COX-2 was induced in the untreated skin of the BK5.EP1 transgenic mice. 
BK5.EP1 transgenic mice produced fewer tumors than did wild type mice, and EP1 
deficient mice produced more tumors, than did wild type mice in the DMBA/TPA skin 
carcinogenesis protocol. Reduced PKC expression in the BK5.EP1 transgenic mice, 
reduced induction of COX-2 after TPA treatment in the BK5.EP1 transgenic mice, and 
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reduced and more transient induction of phosphor-EGFR are possible reasons why 
BK5.EP1 transgenic mice produced fewer tumors in the DMBA/TPA skin carcinogenesis 
protocol. Clearly, COX-2 is a very important down-stream molecule of EP1 signaling, 
especially for inducing tumors in the DMBA-only skin carcinogenesis protocol.  
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